WO2024003350A1 - Polythérapie pour mélanome - Google Patents
Polythérapie pour mélanome Download PDFInfo
- Publication number
- WO2024003350A1 WO2024003350A1 PCT/EP2023/067998 EP2023067998W WO2024003350A1 WO 2024003350 A1 WO2024003350 A1 WO 2024003350A1 EP 2023067998 W EP2023067998 W EP 2023067998W WO 2024003350 A1 WO2024003350 A1 WO 2024003350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- melanoma
- inhibitor
- inhibitors
- expression
- long
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 263
- 238000002648 combination therapy Methods 0.000 title abstract description 14
- 230000014509 gene expression Effects 0.000 claims description 291
- 239000003112 inhibitor Substances 0.000 claims description 197
- 102000039446 nucleic acids Human genes 0.000 claims description 189
- 108020004707 nucleic acids Proteins 0.000 claims description 189
- 150000007523 nucleic acids Chemical class 0.000 claims description 189
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 135
- 206010028980 Neoplasm Diseases 0.000 claims description 88
- 230000002452 interceptive effect Effects 0.000 claims description 87
- 230000000692 anti-sense effect Effects 0.000 claims description 81
- 101000884596 Homo sapiens Putative uncharacterized protein encoded by LINC00518 Proteins 0.000 claims description 77
- 102100038118 Putative uncharacterized protein encoded by LINC00518 Human genes 0.000 claims description 77
- 102000043136 MAP kinase family Human genes 0.000 claims description 73
- 108091054455 MAP kinase family Proteins 0.000 claims description 73
- 238000011282 treatment Methods 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 51
- 230000037361 pathway Effects 0.000 claims description 51
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 41
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 41
- 101710163270 Nuclease Proteins 0.000 claims description 37
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 36
- 238000010362 genome editing Methods 0.000 claims description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 230000004044 response Effects 0.000 claims description 31
- 108091033409 CRISPR Proteins 0.000 claims description 25
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 21
- 229940124647 MEK inhibitor Drugs 0.000 claims description 21
- 102100039788 GTPase NRas Human genes 0.000 claims description 19
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 19
- 229960004066 trametinib Drugs 0.000 claims description 19
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 18
- 108090000994 Catalytic RNA Proteins 0.000 claims description 17
- 102000053642 Catalytic RNA Human genes 0.000 claims description 17
- 230000006907 apoptotic process Effects 0.000 claims description 17
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical group S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 17
- 108091092562 ribozyme Proteins 0.000 claims description 17
- 229960002465 dabrafenib Drugs 0.000 claims description 16
- 238000002626 targeted therapy Methods 0.000 claims description 16
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 14
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 14
- 238000010354 CRISPR gene editing Methods 0.000 claims description 13
- 230000015556 catabolic process Effects 0.000 claims description 13
- 238000006731 degradation reaction Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 13
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229960003862 vemurafenib Drugs 0.000 claims description 12
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims description 11
- 238000002512 chemotherapy Methods 0.000 claims description 11
- 229960002271 cobimetinib Drugs 0.000 claims description 10
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 10
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims description 10
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 10
- 229950003054 binimetinib Drugs 0.000 claims description 9
- 229950001969 encorafenib Drugs 0.000 claims description 9
- 229950010746 selumetinib Drugs 0.000 claims description 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 8
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 8
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 8
- 238000010459 TALEN Methods 0.000 claims description 8
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 7
- 208000021039 metastatic melanoma Diseases 0.000 claims description 7
- 229940124204 C-kit inhibitor Drugs 0.000 claims description 6
- 101000962088 Homo sapiens NBAS subunit of NRZ tethering complex Proteins 0.000 claims description 3
- 102100039210 NBAS subunit of NRZ tethering complex Human genes 0.000 claims description 3
- 108091030071 RNAI Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 139
- 125000003729 nucleotide group Chemical group 0.000 description 120
- 239000002773 nucleotide Substances 0.000 description 118
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 88
- 108090000623 proteins and genes Proteins 0.000 description 71
- 239000002777 nucleoside Substances 0.000 description 56
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 45
- 230000009368 gene silencing by RNA Effects 0.000 description 45
- 239000004055 small Interfering RNA Substances 0.000 description 42
- 125000003835 nucleoside group Chemical group 0.000 description 39
- 230000008685 targeting Effects 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 32
- 230000000295 complement effect Effects 0.000 description 31
- 230000035772 mutation Effects 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 26
- 150000003833 nucleoside derivatives Chemical class 0.000 description 24
- 101000901942 Homo sapiens ATP-dependent DNA/RNA helicase DHX36 Proteins 0.000 description 23
- 108020004459 Small interfering RNA Proteins 0.000 description 23
- 102100022410 ATP-dependent DNA/RNA helicase DHX36 Human genes 0.000 description 21
- 108091027967 Small hairpin RNA Proteins 0.000 description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 20
- 230000009467 reduction Effects 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 239000000523 sample Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000003197 gene knockdown Methods 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 208000030381 cutaneous melanoma Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 12
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 11
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 11
- 210000002752 melanocyte Anatomy 0.000 description 11
- 238000003753 real-time PCR Methods 0.000 description 11
- 201000003708 skin melanoma Diseases 0.000 description 11
- 108700024394 Exon Proteins 0.000 description 10
- 239000012472 biological sample Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 9
- 201000005969 Uveal melanoma Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 108020005004 Guide RNA Proteins 0.000 description 8
- 238000003559 RNA-seq method Methods 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000030279 gene silencing Effects 0.000 description 8
- 238000003119 immunoblot Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102000003952 Caspase 3 Human genes 0.000 description 7
- 108090000397 Caspase 3 Proteins 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 108091084619 miR-125b-1 stem-loop Proteins 0.000 description 7
- 108091063409 miR-125b-2 stem-loop Proteins 0.000 description 7
- 108091050014 miR-125b-3 stem-loop Proteins 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 229930024421 Adenine Natural products 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940113082 thymine Drugs 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 5
- 108091007717 SAMMSON Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- -1 methoxyethyl Chemical group 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 102200124923 rs121913254 Human genes 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 4
- 206010024218 Lentigo maligna Diseases 0.000 description 4
- 208000007256 Nevus Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000037437 driver mutation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 238000005065 mining Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 201000003731 mucosal melanoma Diseases 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 3
- 101000808654 Homo sapiens Ubiquitin conjugation factor E4 A Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 229940126560 MAPK inhibitor Drugs 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 108091033411 PCA3 Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 3
- 102100038532 Ubiquitin conjugation factor E4 A Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 206010072449 Desmoplastic melanoma Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 102220605841 GTPase HRas_Q61V_mutation Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 2
- 101000753286 Homo sapiens Transcription intermediary factor 1-beta Proteins 0.000 description 2
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108020005198 Long Noncoding RNA Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000032452 Nevus, Epithelioid and Spindle Cell Diseases 0.000 description 2
- 206010029488 Nodular melanoma Diseases 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 2
- 102100022012 Transcription intermediary factor 1-beta Human genes 0.000 description 2
- 241000006770 Xenia Species 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 208000006431 amelanotic melanoma Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000008519 endogenous mechanism Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical compound O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001613 integumentary system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000010189 intracellular transport Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000001439 malignant skin fibrous histiocytoma Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 201000000032 nodular malignant melanoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 102220117341 rs11554290 Human genes 0.000 description 2
- 102200006520 rs121913240 Human genes 0.000 description 2
- 102200006525 rs121913240 Human genes 0.000 description 2
- 102200006539 rs121913529 Human genes 0.000 description 2
- 102200006533 rs121913535 Human genes 0.000 description 2
- 102200007373 rs17851045 Human genes 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000012174 single-cell RNA sequencing Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000011584 spitz nevus Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000037316 sun-exposed skin Effects 0.000 description 2
- 208000030457 superficial spreading melanoma Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 208000019448 vaginal melanoma Diseases 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 101100282111 Caenorhabditis elegans gap-2 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102100024827 Dynamin-1-like protein Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101001044612 Homo sapiens Density-regulated protein Proteins 0.000 description 1
- 101000909218 Homo sapiens Dynamin-1-like protein Proteins 0.000 description 1
- 101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 1
- 101001130433 Homo sapiens Ras-related protein Rap-2c Proteins 0.000 description 1
- 101000800310 Homo sapiens Ubiquitin domain-containing protein TINCR Proteins 0.000 description 1
- 101000841301 Homo sapiens Utrophin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 101150040839 LINC00518 gene Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 108091007767 MALAT1 Proteins 0.000 description 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101800001162 Protein p32 Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100031420 Ras-related protein Rap-2a Human genes 0.000 description 1
- 102100031422 Ras-related protein Rap-2c Human genes 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 description 1
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033084 Ubiquitin domain-containing protein TINCR Human genes 0.000 description 1
- 238000001772 Wald test Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 208000028610 heart and brain malformation syndrome Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002806 hypometabolic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940083118 mekinist Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 229940081616 tafinlar Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Definitions
- the present invention relates to the field of oncology. More particularly, the present invention relates to a new combination therapy for use in treating melanoma.
- Melanoma a highly aggressive cancer that develops from pigment-producing cells known as melanocytes, is the most dangerous and deadly type of skin cancer. It has become a major public health concern due to its incidence steadily rising over recent decades.
- Melanoma patients are typically treated either by surgery at early stages, or by a combination of surgery, chemotherapy, targeted therapy and/or immunotherapy once the cancer has disseminated. Yet, the therapeutic rate is not satisfactory across patients, especially for those with distant metastasis. While detection of the disease in early stage may be curable (in the USA, the five-year survival rate after treatment is 99% for localized disease), later-stage disease that has spread has a relatively poor prognosis, with a median survival of less than 10 months for the most advanced melanoma (in the USA, the five-year survival rate after treatment is 65% when spread to lymph nodes, and only 25% with distant spread). Even if targeted therapy and immunotherapy have improved the overall survival of melanoma patients, some patients still fail to respond or become rapidly resistant to therapy.
- melanoma tumors are indeed notoriously heterogeneous comprising cell populations with distinct properties and gene expression signatures.
- BRAF and NRAS mutations which activate the mitogen-activated protein kinase (MAPK) pathway, are frequently observed mutations in melanoma patients, yet therapies targeting these particular mutations have either proved to be toxic and/or leading to a relapse after rapid tumor regression.
- MAPK mitogen-activated protein kinase
- melanoma subpopulations Molecular characterisation of melanoma subpopulations is therefore needed to facilitate the design of more sophisticated combinatorial approaches to reduce heterogeneity and improve therapeutic response.
- some vulnerabilities common to most melanoma cell states have been identified and successfully exploited to overcome therapy resistance, with a clear example being inhibition of mitochondrial function that impacts viability of multiple melanoma states irrespective of driver mutations leading to long lasting antitumor response.
- LncRNAs Long non-coding (Lnc)RNAs, a form of non-coding RNA over 200 nucleotides in length that have low protein-coding potential, have recently emerged as important regulators of virtually every process in the cell, in particular adaptive processes involved in tumor progression and therapy resistance.
- IncRNAs LINC00518 (also known as LENOX) and LINC00520 have been identified as weakly expressed in healthy melanocytes yet highly upregulated in all known melanoma states (but not in other human tumors); their use as suitable diagnostic markers for melanoma and/or as suitable targets for treatment of melanoma, irrespective of phenotype or mutation status, has been reported (W02021/152005; Luan et al. Journal of Experimental & Clinical Cancer Research 2020, 39:96; Huang et al. BMC Pulm Med,2C2 ⁇ , 21 :287).
- the present Inventors are herein the first to investigate an innovative therapeutic approach aimed at targeting the two melanoma-specific IncRNAs (i) LINC00520 and (ii) LINC00518, by knocking-down their respective functional expression.
- the inventors assessed the efficacy of this proof-of-concept in melanoma cells that are either melanocytic or undifferentiated (mesenchymal), with different mutational status (e.g. BRAF or RNAS), using an antisense targeting LINC00520 in combination with an antisense targeting LINC00518. Testing these two types of cells is important since those that are melanocytic are typically involved in the proliferative aspect of melanoma, while those of mesenchymal phenotype are generally responsible for the invasion and resistance to therapy.
- LINC00520 underlying the promotion of melanoma cell proliferation and metastasis is not via the miR-125b-5p/ EIF5A2 pathway as alleged in the art (Luan et al. Journal of Experimental & Clinical Cancer Research 2020, 39:96), but rather via the RNA helicase DHX36.
- LINC00520 and LINC005108 co-inhibition of the functional expression of LINC00520 and of the mitogen-activated protein kinase (MAPK) pathway can effectively promote melanoma cell death in a synergistic manner, notably in melanocytic melanoma cells that are sensitive to MAPK inhibition.
- MAPK mitogen-activated protein kinase
- the invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 for use in combination with (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, in the treatment of a melanoma.
- the inhibitors (each and/or in combination) increase the apoptosis and/or decrease the proliferation of melanoma cells.
- the inhibitors (each and/or in combination) increase apoptosis and/or decrease the proliferation of melanoma cells, independent of BRAF and/or NRAS status.
- the melanoma is an advanced melanoma or a metastatic melanoma.
- the melanoma is a melanocytic melanoma.
- the melanoma is a cutaneous or ocular (e.g. uveal) melanoma, especially a cutaneous or ocular (e.g. uveal) melanocytic melanoma.
- the melanoma is a resistant melanoma, in particular a melanoma resistant to chemotherapy, targeted therapy, and/or immune checkpoint inhibitors.
- each inhibitor is either a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA, or is a genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA.
- the nucleic acid molecule interfering specifically with the expression of the long-non coding RNA is an antisense nucleic acid, an RNAi nucleic acid, or a ribozyme, preferably is an antisense nucleic acid.
- the antisense nucleic interfering specifically with the expression of the long-non coding RNA induces a RNAse H mediated degradation.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA is a gapmer.
- the antisense is an LNA antisense and/or comprises phosphothiorate linkages, preferably the gapmer is an LNA gapmer and/or comprises phosphothiorate linkages.
- the genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA is the CRISPR/Cas system, the Zinc-finger nuclease (ZFN) system, the TALEN system, or the meganuclease system, preferably is the CRISPR/Cas system such as the CRISPR/Cas9 system.
- the invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described herein, as a combined preparation for simultaneous, separate or sequential use in the treatment of a melanoma.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described herein, and optionally (iii) a pharmaceutically acceptable excipient.
- the invention relates to an in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors of the invention, said method comprising: a) determining the respective expression level of the long-non coding RNAs (IncRNAs) LINC00520 and LINC00518, in a melanoma tumor sample; b) comparing the expression level determined in step a) with a reference expression level for each of said IncRNA, thereby identifying whether the melanoma tumor is suitable for said treatment.
- IncRNAs long-non coding RNAs
- the invention relates to a kit for use in the in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors of the invention, said kit comprising: a) at least one reagent capable of specifically determining the expression level of the long-non coding RNA (IncRNA) LINC00520; and b) at least one reagent capable of specifically determining the expression level of the long-non coding RNA (IncRNA) LINC00518; c) optionally, instructions for performing said method.
- a kit for use in the in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors of the invention comprising: a) at least one reagent capable of specifically determining the expression level of the long-non coding RNA (IncRNA) LINC00520; and b) at least one reagent capable of specifically determining the expression level of the long-non coding RNA (IncRNA) LINC00518; c) optionally,
- the invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 for use in combination with (ii) an inhibitor of the mitogen-activated protein kinase (MAPK) pathway, in the treatment of a melanoma.
- IncRNA long-non coding RNA
- MAPK mitogen-activated protein kinase
- the inhibitors (each and/or in combination) increase the apoptosis and/or decrease the proliferation of melanoma cells.
- the inhibitors (each and/or in combination) increase apoptosis and/or decrease the proliferation of melanoma cells, independent of BRAF and/or NBAS status.
- the melanoma is an advanced melanoma or a metastatic melanoma.
- the melanoma is a melanocytic melanoma.
- the melanoma is a cutaneous or ocular (e.g. uveal) melanoma, especially a cutaneous or ocular (e.g. uveal) melanocytic melanoma.
- the melanoma is a resistant melanoma, in particular a melanoma resistant to chemotherapy, targeted therapy, and/or immune checkpoint inhibitors.
- the melanoma is not resistant to targeted inhibition of the mitogen-activated protein kinase (MAPK) pathway, especially not resistant to a BRAF inhibitor, a MEK inhibitor or any combination thereof.
- MAPK mitogen-activated protein kinase
- the (i) inhibitor of the long-non coding RNA (IncRNA) LINC00520 is either a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA, or is a genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA.
- the nucleic acid molecule interfering specifically with the expression of the long-non coding RNA is an antisense nucleic acid, an RNAi nucleic acid, or a ribozyme, preferably is an antisense nucleic acid.
- the antisense nucleic interfering specifically with the expression of the long-non coding RNA induces a RNAse H mediated degradation.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA is a gapmer.
- the antisense is an LNA antisense and/or comprises phosphothiorate linkages, preferably the gapmer is an LNA gapmer and/or comprises phosphothiorate linkages.
- the genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA is the CRISPR/Cas system, the Zinc-finger nuclease (ZFN) system, the TALEN system, or the meganuclease system, preferably is the CRISPR/Cas system such as the CRISPR/Cas9 system.
- the (ii) inhibitor of the mitogen-activated protein kinase (MAPK) pathway is a BRAF inhibitor, a MEK inhibitor, a C-Kit inhibitor, or any combination thereof; preferably is a BRAF inhibitor, a MEK inhibitor or a combination thereof.
- the BRAF inhibitor is dabrafenib, vemurafenib, or encorafenib, or any combination thereof.
- the MEK inhibitor is trametinib, cobimetinib, binimetinib, selumetinib, or any combination thereof.
- the MAPK inhibitor is a combination of BRAF inhibitor and a MEK inhibitor, such as a combination of dabrafenib and trametinib.
- the invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of the mitogen-activated protein kinase (MAPK) pathway, as described herein, as a combined preparation for simultaneous, separate or sequential use in the treatment of a melanoma.
- IncRNA long-non coding RNA
- MAPK mitogen-activated protein kinase
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of the mitogen-activated protein kinase (MAPK) pathway, as described herein, and optionally (iii) a pharmaceutically acceptable excipient.
- IncRNA long-non coding RNA
- MAPK mitogen-activated protein kinase
- the invention relates to an in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors of the invention, said method comprising: a) determining, in a melanoma tumor sample, (i) the expression level of the long-non coding RNA (IncRNA) LINC00520, and (ii) the response to an inhibitor of the mitogen-activated protein kinase (MAPK) pathway; b) comparing the expression level determined in step a) with a reference expression level for said IncRNA, and comparing the response determined in step a) with a reference response to said inhibitor, thereby identifying whether the melanoma tumor is suitable for said treatment.
- a determining, in a melanoma tumor sample (i) the expression level of the long-non coding RNA (IncRNA) LINC00520, and (ii) the response to an inhibitor of the mitogen-activated protein kinase (MAPK) pathway
- the invention relates to a kit for use in the in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors of the invention, said kit comprising: a) at least one reagent capable of specifically determining (i) the expression level of the long-non coding RNA (IncRNA) LINC00520; and b) at least one reagent capable of determining (ii) the response to an inhibitor of the mitogen-activated protein kinase (MAPK) pathway; c) optionally, instructions for performing said method.
- a reagent capable of specifically determining (i) the expression level of the long-non coding RNA (IncRNA) LINC00520 and b) at least one reagent capable of determining (ii) the response to an inhibitor of the mitogen-activated protein kinase (MAPK) pathway
- c) mitogen-activated protein kinase
- FIG. 1 The LINC00520 locus is targeted by MITF and its cofactor BRG1.
- FIG. 1 High LINC00520 expression in melanoma.
- RNA-seq data revealed strong up-regulation of LINC00520 expression in melanoma compared to nevi.
- FIG. 3 High LINC00520 expression in the TCGA database of skin cutaneous melanoma data set strongly correlated with poor patent outcome.
- A. Overall high LINC00520 expression correlated with poor patient outcome in SKCM patients. 477 Samples; Quartiles.
- B-C. Separate analysis of primary and metastatic melanoma samples revealed that high LINC00520 expression was favorable in primary tumors, but associated with poor outcome in metastatic tumors. All P- values are shown on the graph.
- FIG. 4 A. LINC00520 RNA levels were determined in the single cell RNA seq data from the collection of uveal melanomas from Pandiani et al. (Cell Death Differ . 2021;28(6): 1990-2000). B. UMAP projection of single cells from the different tumors colored for LINC00520 expression. Tumor LH17.530 is shown by the dotted circle.
- LINC00520 RNA levels were determined in a panel of melanocytic (MM117, IGR-37, SK-MEL-28, 501Mel, SK-MEL-25, MM229, M249, M249R, MM011) and undifferentiated/mesenchymal (IGR-39, SK-MEL-25R, M229R, MM029, MM099, MM047) melanoma cell lines by quantitative PCR (qPCR) using specific primers and normalized on the geometric mean of 5 housekeeping genes.
- the MM011 cell line bears the NRAS mutation Q61K.
- the SK-MEL-25(R), 229(R) and MM099 bear the BRAF mutation V600E and when indicated by R are resistant to BRAF inhibition.
- MM029 carries the BRAFV600K mutation, and MM047 the NRASQ61K mutation and also display moderate MAPKi resistance.
- B. LINC00520 expression was mined in the single cell RNA-seq data set of Rambow et al. (Cell 2018;174(4):843-855.el9 which was based on MEL001 PDX tumors. Only cells where LINC00520 RNAs was captured were included in the analysis. The % of cells analysed for each population is indicated above each bar.
- FIG. 6 The indicated melanoma cells were transfected with a negative control (CTR) or two different antisense oligonucleotides (LNA GapmeRs; GAP#1, GAP#2) targeting LINC00520 and harvested after 48 hours. LINC00520 expression was measured in total RNA by RT-qPCR and compared to the negative control by 1-way Anova (Dunnett’s multiple comparison test).
- CTR negative control
- LNA GapmeRs two different antisense oligonucleotides
- GAP#1, GAP#2 two different antisense oligonucleotides
- B-C Melanoma cells transfected with LINC00520 GapmerRs were stained with the CellTrace Violet dye, cultured for 72 hours and then stained using an anti-cleaved Caspase 3 antibody and analyzed by flow cytometry to determine the number of slow proliferating and apoptotic cells, respectively.
- Active Caspase 3 positive or cells with high CellTrace Violet fluorescence levels were compared to control GapmeR by 1-way Anova (Dunnett’s multiple comparison test).
- Undifferentiated/mesenchymal MM047 melanoma cells and HEKT non-melanoma cells were used as negative controls as they do not express LINC00520.
- D. 501mel and MM117 melanocytic melanoma cells were transfected with LINC00520 targeting GapmeRs and after 72 hours stained with Annexin V and TOPRO-3 and analysed by flow cytometry.
- FIG. 7 A. Expression of miR-125b-5p and LINC00520 was assessed in RNA-seq data from the indicated cell lines expressed as normalized reads per kilobase/transcript length (RPK). B. Analysis of EIF5A2 levels in the TCGA SKCM database did not show a statistically significant association with patient survival.
- FIG. 8 A. Immunoblots of proteins co-purified with LINC00520 or PC A3 under native of UV-crosslinked conditions.
- N 4 independent biological replicates.
- FIG. 10 A. Volcano plot showing identification of RNAs displaying increased or decreased association with DHX36 following LINC00520 silencing.
- FIG. 11 A-B. Melanoma cells were transfected with suboptimal doses of GapmeRs targeting LINC00518 or LINC00520 as single agents or in pairwise combination. Cells were stained with the CellTrace Violet dye, cultured for 72 hours, stained with an anti -cleaved Caspase 3 antibody and analyzed by flow cytometry. Percentages of apoptotic caspase 3-positive cells (A) and low proliferative cells (B) were compared between the groups by 1-way Anova. C. Expression of LINC00518 and LINC00520 was analyzed by RT-qPCR as described above.
- the present invention aims at providing an innovative therapeutic approach for the treatment of melanoma, regardless of its phenotype, driver mutations or resistance to therapy, by inhibiting the functional expression of two melanoma-specific IncRNAs: LINC00520 and LINC00518.
- the present invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 for use in combination with (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, in the treatment of a melanoma.
- the present invention is directed to the combined use of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, for the preparation of a medicament for the treatment of a melanoma.
- a method for treating a melanoma comprising the administration, to said subject, of a therapeutically effective amount of: (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518.
- a “long-non coding RNA” (long ncRNA, or IncRNA) is generally referred as a non-coding RNA that is at least 200 nucleotides in length.
- a particular class of IncRNA are “long intergenic noncoding RNAs” (lincRNAs), which are sequences of IncRNA transcribed from non-coding DNA sequences between protein-coding genes.
- LINC00518 also known as “LENOX” or” C6orf218”, refers to the long intergenic non-protein coding RNA 518. It is disclosed in the GeneCards database under ID GC06M0 10428, in the HGNC database under ID 28626, in the Gene database under ID 221718, in the Ensembl database under ID ENSG00000183674 and in the Genbank database under NR_027793.
- the LINC00518 gene encodes 8 splicing variants (i.e. isoforms), arising from up to 4 exons (see Table 1). Unless specified otherwise, the term “LINC00518” encompasses all the isoforms thereof.
- LINC00520 Long intergenic non-protein coding RNA 520
- C14orf34 Long intergenic non-protein coding RNA 00520
- LASSIE Long intergenic non-protein coding RNA 00520
- the LINC00520gene encodes 12 splicing variants (i.e. isoforms), arising from up to 5 exons (see Table 2). Unless specified otherwise, the term “LINC00520” encompasses all the isoforms thereof.
- telomere By ‘functional expression” of a gene, it is meant the transcription and/or translation of functional gene product.
- an “inhibitor of functional expression” of a gene refers to a molecule or technical means capable of decreasing or even abolish the expression of said gene.
- functional expression can be deregulated on at least two levels: first, at the DNA level, e.g. by absence or disruption of the gene, or lack of transcription taking place (in both instances preventing synthesis of the relevant gene product); second, at the RNA level, e.g. by lack of splicing or lack or decrease in the activity mediated by said IncRNA. Inhibition can be evaluated by any means known to those skilled in the art including, but not limited to, assessing the level of IncRNA transcript using e.g. quantitative PCR.
- the inhibitor is selective, or in other words, specific for the targeted IncRNA, in that it does not inhibit, or at least does not substantially inhibit, any other target.
- An inhibitor according to the invention is capable of inhibiting the functional expression of the IncRNA in vivo and/or in vitro.
- the inhibitor may inhibit the functional expression of the IncRNA by at least about 10%, 15% 20%, or 25%, preferably by at least about 30%, 35%, 40% or 45%, still preferably by at least about 50%, 55%, 60%, or 65%, yet preferably by at least about 70%, 75%, 80%, or 85%, more preferably by at least about 90%, or 95%.
- treatment means obtaining a desired physiological or pharmacological effect depending on the degree of severity of the symptom or disorder of interest, or risks thereof, i.e. herein, depending on the degree of severity or risks of developing such symptom or disorder.
- this includes, inter alia, the alleviation of symptoms, the reduction of inflammation, the inhibition of cancer cell growth, and/or the reduction of tumor size.
- these terms are intended to encompass curing as well as ameliorating at least one symptom of the condition or disease.
- a response to treatment includes a reduction in cachexia, increase in survival time, elongation in time to tumor progression, reduction in tumor mass, reduction in tumor burden and/or a prolongation in time to tumor metastasis, time to tumor recurrence, tumor response, complete response, partial response, stable disease, progressive disease, progression free survival, overall survival, each as measured by standards set by the National Cancer Institute and the U.S. Food and Drug Administration for the approval of new drugs. See Johnson et al., J. Clin. Oncol., 2009; 21(7): 1404-1411.
- the term treatment refers to the inhibition or reduction of cancer cell proliferation and/or the increase in cancer cell apoptosis in a subject having the cancer, herein melanoma.
- the inhibition or reduction of cancer cells and/or the increase in apoptosis of cancer cells is independent of the status of tumor-associated proteins, herein independent of BRAF and/or NRAS status.
- tumor-associated proteins e.g. BRAF status, NRAS status
- melanoma cells cells of interest
- the term is used in the sense “irrespective of or “independent of status, meaning that an effect is observed irrespective of expression levels of, or presence of mutations in, the particular protein in the cells of interest (herein, melanoma cells).
- BRAF mutations are more commonly observed in intermittently sun-exposed skin, and associated with KIT mutations, which are present predominantly in mucosal and acral melanomas.
- BRAF mutations associated with melanoma include, without limitation, R461I, I462S, G463E, G463V, G465A, G465E, G465V, G468A, G468E, N580S, E585K, D593V, F594L, G595R, L596V, T598I, V599D, V599E, V599K, V599R, V600E/K (the most prominent), K600E, A727V, and most of these mutations are clustered to two regions: the glycine-rich P loop of the N lobe and the activation segment and flanking regions.
- the BRAF mutation is V600E/K, preferably V600E.
- NRAS mutations are more commonly observed in older patients (above 55 years-old), with a chronic pattern of UV exposure with lesions are usually located at the extremities.
- Examples of NRAS mutations typically associated with melanoma include, without limitation, G12D/C, G13R, Q61K, Q61R, Q61L, Q61V, Q61H, Q61P.
- the NRAS mutation is Q61K/R.
- a “therapeutically effective amount' means herein an amount that is sufficient to achieve the effect for which it is indicated, herein the treatment of a melanoma.
- the amount of the combination therapy of the invention to be administered can be determined by standard procedures well known by those of ordinary skill in the art. Physiological data of the patient (e.g. age, size, and weight), the routes of administration and the disease to be treated have to be taken into account to determine the appropriate dosage, optionally compared with subjects that do not suffer from a melanoma. The amount may also vary according to other components of a treatment protocol (e.g. administration of other medicaments, etc.).
- a “subtherapeutic amount” or “subtherapeutic dose” is an amount that is not therapeutically effective if administered in absence of any other agent or therapy.
- the “subject” or “patients” to be treated according to the invention is one having an integumentary system. Accordingly, preferred subjects to be treated are animals, more preferably mammals, most preferably humans.
- melanoma also known as “malignant melanoma”, refers to a type of cancer that develops from the pigment-producing cells called melanocytes.
- melanocytes There are three main categories of melanoma: cutaneous melanoma, the most common, which corresponds to the melanoma of the skin; mucosal melanoma which can affect any mucous membrane of the body, including the nasal passages, throat, vagina, anus, or mouth; and ocular melanoma, which is a rare form of melanoma affecting the eye (also known as uveal or choroidal melanoma).
- the melanoma to be treated can be at any stage.
- the melanoma can be at stage VII, II, III, or IV, preferably stage II, III, or IV, more preferably stage III, or IV.
- the melanoma can be at stage Tla, Tib, T2a, T2b, T3a, T4a, T4b, Nl, N2, N3, Mia, Mlb, or Mlc, preferably stage T2b, T3a, T4a, T4b, Nl, N2, N3, Mia, Mlb, or Mlc.
- the melanoma is at an advanced or metastatic stage.
- the melanoma can be preferably selected from the group consisting of lentigo maligna, lentigo maligna melanoma, superficial spreading melanoma, acral lentiginous melanoma, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, melanoma with small nevus-like cells, melanoma with features of a Spitz nevus, uveal melanoma, Harding-Passey melanoma, juvenile melanoma, amelanotic melanoma, Cloudman's melanoma, and vaginal melanoma.
- the melanoma is a melanocytic melanoma.
- the melanoma is a cutaneous or ocular (e.g. uveal) melanoma.
- the melanoma is a cutaneous or ocular (e.g. uveal) melanocytic melanoma.
- resistant melanoma refers to a melanoma, which does not respond to a conventional treatment for said cancer.
- the cancer may be resistant at the beginning of treatment or it may become resistant during treatment or does not respond anymore. The resistance to the treatment may lead to rapid progression of metastatic of melanoma.
- the melanoma can be resistant to a targeted therapy, especially inhibitors of the MAPK pathway which include BRAF inhibitors, MEK inhibitors and C-Kit inhibitors; to chemotherapy; and/or to immune checkpoint inhibitors.
- the melanoma is resistant to a targeted therapy, especially BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib, and/or MEK inhibitors, such as trametinib, cobimetinib, binimetinib, or selumetinib, or any combination thereof.
- BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib
- MEK inhibitors such as trametinib, cobimetinib, binimetinib, or selumetinib, or any combination thereof.
- the inhibitors of functional expression according to the invention may indeed restore or increase the sensitivity of melanoma to this type of therapy.
- the melanoma may not be resistant to a targeted therapy, especially inhibitors of the MAPK pathway which include BRAF inhibitors, MEK inhibitors and C-Kit inhibitors; to chemotherapy; and/or to immune checkpoint inhibitors.
- the melanoma is not resistant to a targeted therapy, especially BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib, and/or MEK inhibitors, such as trametinib, cobimetinib, binimetinib, selumetinib, or any combination thereof.
- BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib
- MEK inhibitors such as trametinib, cobimetinib, binimetinib, selumetinib, or any combination thereof.
- the inhibitors of functional expression according to the invention may indeed prevent, decrease or delay the appearance of a resistance to such therapy.
- the melanoma whether the melanoma is resistant or not, the melanoma can be associated with a BRAF mutation and/or with a NRAS mutation, as described above.
- the present invention requires a combined inhibition of two melanoma-specific IncRNAs: LINC00520 and LINC00518.
- Inhibitors of functional expression of LINC00520 and LINC00518 have been reported in the scientific and patent literature (W02021/152005; Luan et al. Journal of Experimental & Clinical Cancer Research (2020) 39:96; Huang et al. BMC Pulm Med (2021) 21 :287; the contents of which are incorporated herein by reference in their entireties). Below is provided a non-exhaustive list of such inhibitors which can be used in the present invention.
- each of the inhibitors of functional expression used in the present invention can preferably be either a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA, or a genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA.
- a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA might be preferred should one wish to inhibit functional expression at the RNA level, while a genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA might be preferred should one wish to inhibit functional expression at the DNA level.
- the inhibitor used in the present invention can be a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA.
- nucleic acid molecule refers to a succession of natural or synthetic nucleotides (or nucleosides) connected by intemucleotide (or intemucleoside) linkages, wherein each nucleotide (or nucleoside) or internucleotide (or intemucleoside) linkages may be modified or unmodified.
- a nucleotide is comprised of a nucleoside and a phosphate group.
- a nucleoside is comprised of a nucleobase and a sugar.
- a nucleobase comprises a modified and unmodified nucleobase.
- Unmodified nucleobases are well-known in the art and include adenine (A), thymine (T), cytosine (C), uracil (U) and guanine (G).
- An internucleotide (intemucleoside) linkage is a bond that forms a covalent linkage between adjacent nucleotides (nucleosides) in a nucleic acid, such as phosphate intemucleotide linkages that are naturally occurring.
- a nucleic acid may be a single-stranded or double-stranded DNA such as cDNA, genomic DNA, ribosomal DNA, and the transcription product of said DNA, such as RNA.
- Nucleic acids also encompass nucleic acids which can hybridize to a nucleic acid of reference.
- a nucleic acid When a nucleic acid is designed to hybridize to a nucleic acid of reference, it can be chemically modified to enhance its stability, nuclease resistance, target specificity and/or improve their pharmacological properties (e.g. reduced toxicity, increased intracellular transport, etc.).
- a nucleic acid may comprise modified nucleotide(s) and/or backbone, such as a modified sugar, a modified nucleobase, and/or a modified intemucleotide (intemucleoside) linkage.
- a standard modification is the replacement of native phosphates of the internucleotide (intemucleoside) linkage with phosphorothioates (PS) so as to reduce the sensitivity to nucleases and accordingly improve the stability, half-life and tissue distribution of the nucleic acid (Eckstein F., Antisense and Nucleic Acid Drug Development, 2000, 10(2): 1117-221).
- PS phosphorothioates
- Preferred nucleic acid molecules interfering specifically with the expression of the long-non coding RNA according to the invention are those capable of hybridizing specifically to the gene or transcripts of the IncRNA, at least to a part thereof; as such, these are usually non-naturally occurring nucleic acids (i.e. synthetic).
- Hybridizing or “hydridization” means the pairing or annealing to a target, herein under physiological conditions, typically via hydrogen bonding between complementary nucleotides, such as Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding.
- a specific hybridization therefore means that the pairing or annealing is specific to the target (no off-targets effects, or at least no substantial off-targets effects).
- a nucleic acid molecule capable of hybridizing to a target nucleic acid thus means that a stretch of this nucleic acid is capable of forming base pairs to another stretch of the target nucleic acid. It is thus not absolutely required that all the bases in the region of complementarity are capable of pairing with bases in the opposing strand. Mismatches may be tolerated to some extent, as long as in the circumstances, the stretch of nucleotides is capable of hybridizing to its complementary part.
- the nucleic acid molecule interfering specifically with the expression of the long-non coding RNA is preferably an antisense nucleic acid, an RNAi nucleic acid, or a ribozyme.
- antisense nucleic acid' or “antisense oligonucleotides” designates a synthetic single-stranded oligonucleotide of which the sequence is at least partially complementary to a target nucleic acid, such as to the RNA sequence of a target gene (Lee et al., J Cardiovasc Transl Res. 2013; 6(6):969-80; DeVos et al., Neurotherapeutics 2013; 10(3):486-972013).
- An antisense nucleic acid is capable of altering the expression of a specific target gene, either by splicing modification, or by recruiting RNAse H leading to RNA degradation of RNA-DNA duplexes, thus blocking the expression of the target gene.
- An antisense nucleic acid is typically short in length, in general 5 to 50 nucleotides in length, such as 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length, more preferably 10, 15, 20, 25, 30, 35 nucleotides in length. It is well within the skill of the person in the art to design antisense nucleic acids specific to a target, based on the knowledge of a target sequence such as introns, exons, or 5’CAP (DeVos et al., Neurotherapeutics 2013; 10(3):486-972013). Antisense nucleic acids can be prepared by methods well-known in the art, such as by chemical synthesis and enzymatic ligation reactions.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA inhibits the splicing of the pre- long-non coding RNA, or in other words, it inhibits the formation of the mature long-non coding RNA.
- An antisense nucleic acid can indeed be designed to block a splice acceptor (SA) site and/or an exon splicing enhancer (ESE) and/or any sequence which could modulate a pre-RNA splicing, i.e. it can be designed to be complementary to a part of the pre-RNA comprising an SA, an ESE, or any sequence which could modulate its splicing.
- SA splice acceptor
- ESE exon splicing enhancer
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA induces a RNAse H mediated degradation.
- RNAse H is a cellular enzyme which recognizes duplex between DNA and RNA, and enzymatically cleaves the RNA molecules.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA comprises a region that comprises DNA or DNA-like nucleotides complementary to the targeted IncRNA which is responsible for RNAse H recruitment, ultimately leading to the cleavage of the target nucleic acid.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA is complementary to all or part of the IncRNA, preferably to a part thereof, such as any one of its exons or introns. Sequences of LINC00520 and LINC00518 are well known in the art, as explained above.
- the antisense nucleic acid interfering specifically with the expression of LINC00518 comprises or consists of a contiguous nucleotide sequence of at least 10 to 30 (preferably 11 to 29, 12 to 26, 13 to 24, 14 to 22, 14 to 17, 14, 15 or 16) nucleotides in length that is complementary to a specific region of the LINC00518 sequence.
- Non limiting examples of such antisense nucleic acids include, without limitation, those comprising or consisting of a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 2 or 3, such as those comprising or consisting of the sequence SEQ ID NO: 2 or 3.
- the antisense nucleic acid interfering specifically with the expression of LINC00520 comprises or consists of a contiguous nucleotide sequence of at least 10 to 30 (preferably 11 to 29, 12 to 26, 13 to 24, 14 to 22, 14 to 17, 14, 15 or 16) nucleotides in length that is complementary to a specific region of the LINC00520 sequence.
- Non limiting examples of such antisense nucleic acids include, without limitation, those comprising or consisting of a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 4 or 5, such as those comprising or consisting of the sequence SEQ ID NO: 4 or 5.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA may further comprise at least one modified sugar, at least one modified internucleotide (or internucleoside) linkage, and/or at least one modified nucleobase, so as to enhance its properties, such a reduction in sensitivity to nucleases, increase in stability, half-life and/or tissue distribution, and/or enhancement of its affinity towards its target nucleic acid.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA comprises at least one modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-0-Me), 2’fluoro (2’-F), 2’0- methoxyethyl (2’-M0E also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl).
- a “modified sugar” is a sugar that is non-naturally occurring.
- 2’,4’-brigded which is the introduction of a methylene bridge between the 2’ and 4’ position of the nucleotide, defining locked nucleic acids (LNA), is herein particularly preferred so as to confer or increase the stability of a nucleic acid when hybridized to a complementary DNA or RNA nucleic acid.
- LNA locked nucleic acids
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA comprises at least one modified intemucleotide (or internucleoside) linkage, such as a phosphorothioate intemucleotide (or internucleoside) linkage.
- a “modified internucleotide linkage” is an intemucleotide (or intemucleoside) linkage in a nucleic acid that is non-naturally occurring, and is thus referred as a non-phosphate linkage.
- a phosphorothioate linkage which is a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom, is herein particularly preferred so as to confer or increase the resistance of a nucleic acid to nucleases.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA is a gapmer.
- a “gapmer” refers to a nucleic acid molecule comprising an internal segment having a plurality of nucleotides (or nucleosides) that support RNase H cleavage positioned between external segments, each having one or more nucleotides (or nucleosides), wherein the nucleotide (or nucleosides) comprising the internal segment are chemically distinct from the immediately adjacent nucleotide(s) (or nucleoside(s)) comprising the external segments.
- the internal or central segment may be referred to as the “gap”, “gap segment” or “gap region” (G); while the external segments may be referred to as the “wings”, “flanks”, “wing segments” , “flank segments” , “wing regions” or “flank regions” (F for the 5’ flank region and F’ for the 3’ flank region).
- the F and F’ regions are composed of modified ribonucleotides (RNA*) which are complementary to a target nucleic acid;
- the G region is composed of deoxyribonucleotides, i.e. DNA or DNA-like molecules, which is responsible for RNAse H recruitment which ultimately leads to the degradation of the target nucleic acid.
- Gapmers can typically comprise a gap region (G) of 5 to 15 deoxynucleotides (or deoxynucleosides) flanked by wing regions (F and F’) of 2 to 10 modified nucleotides (or nucleosides) each.
- G gap region
- F and F wing regions
- the gapmer interfering specifically with the expression of the long-non coding RNA comprises or consists of a contiguous nucleotide (or nucleoside) sequence corresponding to the following formula:
- the gapmer interfering specifically with the expression of the long-non coding RNA can comprise or consist of a contiguous nucleotide (or nucleoside) sequence that is complementary to a specific region of the IncNRA sequence and that corresponds to the following formula:
- RNA* 5’-F (RNA*) - G (DNA or DNA-like) - F’ (RNA*)-3’
- the gap segment (G) comprises or consists of a sequence of at least 5 to 15 nucleotides (or nucleosides) in length
- each wing segment (F or F’) comprises at least 2 to 10 nucleotides (or nucleosides) in length
- each nucleotide (or nucleoside) of each wing segment (F and F’) comprises a modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-O-Me), 2’fluoro (2’-F), 2’0-methoxyethyl (2’-MOE also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl), more preferably 2’,4’-brigded, and wherein each intemucleotide (or intem
- the gapmer interfering specifically with the expression of LINC00518 comprises or consists of a contiguous nucleotide (or nucleoside) sequence that is complementary to a specific region of the LINC00518 sequence and that corresponds to the following formula:
- each wing segment (F or F’) comprises at least 2 to 10 nucleotides (or nucleosides) in length, wherein each nucleotide (or nucleoside) of each wing segment (F and F’) comprises a modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-0-Me), 2’fluoro (2’-F), 2’0-methoxyethyl (2’-M0E also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl), more preferably 2’,4’-brigded, and wherein each internucleotide (or intemucleo
- Non limiting examples of gapmers interfering specifically with the expression of LINC00518 include, without limitation, gapmers comprising or consisting of any one of the following sequences: Cbs Cbs Gbs dAs mdCs mdCs dTs dGs dAs dAs dTs dGs Cbs Abs Ab (SEQ ID NO: 10), or Gbs Tbs Abs dGs dAs dGs dGs mdCs dTs dAs dGs dAs Cbs Tbs Gb (SEQ ID NO: 11), wherein A is an adenine, mC is a 5-methylcytosine, G is a guanine, T is a thymine, b is LNA (2',4'-methylene bridged sugar moiety), d is a 2’ -deoxyribosyl sugar moiety, and s is
- the gapmer interfering specifically with the expression of LINC00520 comprises or consists of a contiguous nucleotide (or nucleoside) sequence corresponding to the following formula:
- each wing segment (F or F’) comprises at least 2 to 10 nucleotides (or nucleosides) in length
- each nucleotide (or nucleoside) of each wing segment (F and F’) comprises a modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-0-Me), 2’fluoro (2’-F), 2’0-methoxyethyl (2’-M0E also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl), more preferably 2’,4’-brigded, and
- Non limiting examples of gapmers interfering specifically with the expression of LINC00520 include, without limitation, gapmers comprising or consisting of any one of the following sequences:
- Tbs Tbs Tbs dGs dAs dTs dGs dAs dGs dTs dGs dAs dGs Tbs Cbs Gb (SEQ ID NO: 12)
- Gbs Abs Gbs dTs dmCs dGs dmCs dTs dGs dAs dGs dAs Tbs Tbs Ab (SEQ ID NO: 13) wherein A is an adenine, mC is a 5-methylcytosine, G is a guanine, T is a thymine, b is LNA (2',4'-methylene bridged sugar moiety), d is a 2’ -deoxyribosyl sugar moiety, and s is a phosphorothioate intemucleotide (or intemucleoside) linkage.
- gapmers are well-known in the art, and can be easily conceived by the skilled practitioner. See for example W02021/152005, incorporated herein in its entirety.
- RNAi can be used to inhibit the functional expression of the IncRNA.
- RNAi nucleic acid refers to a nucleic acid that can inhibit expression of a target gene by RNA interference (RNAi) mechanism. By contrast to antisense nucleic acids, RNAi nucleic acids target mature RNA. RNAi nucleic acids are well-known in the art, and include short-hairpin RNA (shRNA), small interfering RNA (siRNA), double-stranded RNA (dsRNA), and single-stranded RNA (ssRNA) (Sohail et al. 2004, Gene Silencing by RNA Interference: Technology and Application 1 st Edition, ISBN 9780849321412; WO 99/32619; Wang et al., Pharm Res 2011, 28:2983-2995).
- shRNA short-hairpin RNA
- siRNA small interfering RNA
- dsRNA double-stranded RNA
- ssRNA single-stranded RNA
- RNA interference designates a phenomenon by which dsRNA specifically suppresses expression of a target gene at post-transcriptional level.
- dsRNA double-stranded RNA molecules
- siRNA short interfering RNA
- RISC another enzyme
- the siRNAs that are naturally produced by Dicer are typically 21-23 bp in length, with a 19 or 20 nucleotides duplex sequence, two-nucleotide 3' overhangs and 5'-triphosphate extremities (Zamore et al. Cell. 2000,101(l):25-33; Elbashir et al. Genes Dev. 2001, 15(2): 188-200; Elbashir et al. EMBO J. 2001, 20(23):6877-88).
- the selected siRNA or shRNA target sequence should be subjected to a BLAST search against EST database to ensure that the only desired gene is targeted.
- RNAi nucleic acid can be of at least about 10 to 40 nucleotides (or nucleosides) in length, preferably about 15 to 30 base nucleotides (or nucleosides) in length.
- siRNA or shRNA can comprise naturally occurring RNA, synthetic RNA, or recombinantly produced RNA, as well as altered RNA that differs from naturally- occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides (or nucleosides).
- Such alterations can include addition of non-nucleotide (or non-nucleoside) material, such as to the end of the molecule or to one or more internal nucleotides (or nucleoside) of the RNAi, including modifications that make the RNAi resistant to nuclease digestion, as described above.
- non-nucleotide (or non-nucleoside) material such as to the end of the molecule or to one or more internal nucleotides (or nucleoside) of the RNAi, including modifications that make the RNAi resistant to nuclease digestion, as described above.
- the nucleic acid molecule interfering specifically with functional expression of the IncRNA is an RNAi nucleic acid, that is complementary to at least one part of the IncRNA, in particular to at least one exon thereof
- the RNAi nucleic acid can be a siRNA or shRNA of at least about 10 to 40 nucleotides (or nucleosides) in length, preferably of about 15 to 30 nucleotides (or nucleosides) in length.
- the RNAi nucleic acid interfering specifically with the expression of LINC00518 comprises or consists of a contiguous nucleotide sequence of at least 10 to 40 (preferably 15 to 30, 16 to 25, 17 to 24, 20, 21, 22 or 23) nucleotides in length that is complementary to a specific region of the LINC00518 sequence.
- Non limiting examples of such RNAi nucleic acid include, without limitation, those comprising or consisting a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 15, preferably those comprising or consisting of the sequence SEQ ID NO: 15.
- the RNAi nucleic acid interfering specifically with the expression of LINC00520 comprises or consists of a contiguous nucleotide sequence of at least 10 to 40 (preferably 15 to 30, 16 to 25, 17 to 24, 20, 21, 22 or 23) nucleotides in length that is complementary to a specific region of the LINC00520 sequence.
- Non limiting examples of such RNAi nucleic acid include, without limitation, those comprising or consisting a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 23, preferably those comprising or consisting of the sequence SEQ ID NO: 23.
- the nucleic acid interfering specifically with the functional expression of the IncRNA is a ribozyme.
- Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Ribozyme molecules specific for a target (herein a IncRNA) can be designed, produced, and administered by methods commonly known to the art (see e.g., Fanning and Symonds (2006) RNA Towards Medicine (Handbook of Experimental Pharmacology), ed. Springer p. 289-303).
- the nucleic acid molecule interfering specifically with the functional expression of LINC00518 is a ribozyme targeting said IncRNA.
- the nucleic acid molecule interfering specifically with the functional expression of LINC00520 is a ribozyme targeting said IncRNA.
- genome editing can be used to inhibit the functional expression of the IncRNA. More specifically, one can use a genome editing system comprising a nuclease engineered to target the IncRNA gene.
- Gene editing is a type of genetic engineering in which DNA is inserted, replaced, or removed from a genome using artificially engineered nucleases, also called molecular scissors. Nucleases create specific double-stranded break (DSBs) at desired locations in the genome, and harness the cell's endogenous mechanisms to repair the induced break by natural processes of homologous recombination (HR) or non-homologous end-joining (NHEJ).
- DSBs double-stranded break
- HR homologous recombination
- NHEJ non-homologous end-joining
- ZFNs zinc finger nucleases
- TALENs transcription activator-like effector nucleases
- Cas9 the CRISPR/Cas system in particular the Cas9 system
- engineered meganucleases re-engineered homing endonucleases.
- Said nucleases can be delivered to the cells either as DNAs or mRNAs, such DNAs or mRNAs and can be engineered to target the IncRNA gene.
- a particularly preferred genome editing system according to the invention is the CRISPR/Cas system in particular the Cas9 system.
- the genome editing system interfering specifically with functional expression of LINC00518 is a CRISPR/Cas system, in particular a CRISPR/Cas9 system, targeting said IncRNA.
- sgRNA single guide RNA
- Non limiting examples of such sgRNA include, without limitation, those comprising or consisting of a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 16, 17 or 18, preferably those comprising or consisting of the sequence SEQ ID NO: 16, 17 or 18, or any combination thereof.
- the genome editing system is a triplet-target CRISPR system, meaning that three guide RNA are used to target LINC00518, such as those described above.
- the genome editing system interfering specifically with functional expression of LINC00520 is a CRISPR/Cas system, in particular a CRISPR/Cas9 system, targeting said IncRNA.
- sgRNA single guide RNA
- Non limiting examples of such sgRNA include, without limitation, those comprising or consisting of a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 19, 20 or 21, preferably those comprising or consisting of the sequence SEQ ID NO: 19, 20 or 21, or any combination thereof.
- the genome editing system is a triplet-target CRISPR system, meaning that three guide RNA are used to target LINC00520, such as those described above.
- any one of the (i) inhibitors of functional expression of the long-non coding RNA (IncRNA) LINC00520, and any one of the (ii) inhibitors of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described herein, can be combined for the purpose of the present invention.
- the inhibitor of functional expression of the long- non coding RNA (IncRNA) LINC00520 is a nucleic acid molecule interfering specifically with the expression of said IncRNA, as described above; and (i) the inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518 is a nucleic acid molecule interfering specifically with the expression of said IncRNA, as described above.
- nucleic acid molecule interfering specifically with the expression of LINC00520 is an antisense nucleic acid, as described above; and (ii) the nucleic acid molecule interfering specifically with the expression of LINC00518 is an antisense nucleic acid, as described above.
- the nucleic acid molecule interfering specifically with the expression of LINC00520 can be an antisense nucleic acid comprising or consisting a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 4 or 5, such as an antisense nucleic acid comprising or consisting of the sequence SEQ ID NO: 4 or 5; and (ii) the nucleic acid molecule interfering specifically with the expression of LINC00518 can be an antisense nucleic acid comprising or consisting a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 2 or 3, such as an antisense nucleic acid comprising or consisting of the sequence SEQ ID NO: 2 or 3.
- the antisense nucleic acid interfering specifically with the expression of LINC00520 is a gapmer, as described above; and (ii) the antisense nucleic acid interfering specifically with the expression of LINC00518 is a gapmer, as described above.
- the gapmer interfering specifically with the expression of LINC00520 is an LNA gapmer and/or comprises phosphothiorate linkages, as described above; and (ii) the gapmer interfering specifically with the expression of LINC00518 is an LNA gapmer and/or comprises phosphothiorate linkages, as described above.
- the gapmer interfering specifically with the expression of LINC00520 can comprise or consist of any one of the following sequences: Tbs Tbs Tbs dGs dAs dTs dGs dAs dGs dTs dGs dAs dGs Tbs Cbs Gb (SEQ ID NO: 12), or Gbs Abs Gbs dTs dmCs dGs dmCs dTs dGs dAs dGs dAs dAs Tbs Tbs Ab (SEQ ID NO: 13); and (ii) the gapmer interfering specifically with the expression of LINC00518 can comprise or consist of any one of the following sequences: Cbs Cbs Gbs dAs mdCs mdCs dTs dGs dAs dTs dGs Cbs Abs
- any one of the (i) inhibitors of functional expression of the long-non coding RNA (IncRNA) LINC00520, and any one of the (ii) inhibitors of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described herein, can be further combined with an additional therapy, especially one that is suited for melanoma. This includes, without limitation, surgery, radiotherapy, chemotherapy, targeted therapy or immune checkpoint therapy, or any combination thereof. Such therapies are well-known in the art, and therefore need not be detailed herein.
- the combination of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described herein, may be suitable for administration to a cell, tissue and/or an organ of individuals affected by or at risk of suffering from a melanoma, and may be administered in vivo, ex vivo or in vitro. Since melanoma affects melanocytes, it is preferred that said cells are melanocytes, and/or that said tissue or organ is the skin or the eye.
- each inhibitor can be delivered as it is to the subject, or be formulated to be compatible with their intended route of administration.
- the combination can be formulated in a combined pharmaceutical composition, or in separate pharmaceutical compositions, in a form suitable for parenteral, oral, transdermal or topical or intraocular administration, such as a liquid suspension, a solid dosage form (granules, pills, capsules or tablets), or a paste or gel.
- parenteral administration such as subcutaneous, intradermal, intravenous; transdermal administration; topical administration; or even intraocular administration.
- compositions according to the invention may notably be formulated to release the combination therapy immediately upon administration or at any predetermined time or time period after administration.
- the combination When formulated within a pharmaceutical composition, the combination can be further combined with a pharmaceutically acceptable excipient.
- a “pharmaceutically acceptable excipient” means an inactive or inert, and therefore nontoxic, component, as it has no pharmacological action itself, which can be used to improve properties of a composition, such as shelf-life, retention time at the application site, consumer acceptance, etc. It includes, without limitation, surfactants (cationic, anionic, or neutral); surface stabilizers; other enhancers, such as preservatives, wetting or emulsifying agents; solvents; buffers; salt solutions; dispersion medium; isotonic and absorption delaying agents, and the like; that are physiologically compatible.
- the combination therapy is provided in a therapeutically effective amount so as to treat the melanoma.
- the amount of each inhibitor is a pediatric dose in monotherapy, or a dose that is subtherapeutic in monotherapy (yet, is such that it is therapeutically effective in the combination therapy of the invention).
- the amount of each inhibitor is a subtherapeutic dose (yet, is such that it is therapeutically effective in the combination therapy of the invention).
- the present invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described above, as a combined preparation for simultaneous, separate or sequential use in the treatment of a melanoma.
- the invention relates to the simultaneous, separate or sequential use of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described above, for the preparation of a medicament for the treatment of a melanoma.
- a method for treating a melanoma comprising the simultaneous, separate or sequential administration, to said subject, of a therapeutically effective amount of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described above.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00518, as described above, and optionally (iii) a pharmaceutically acceptable excipient.
- the present invention pertains to an in vitro method for identifying a melanoma tumor suitable for the combined treatment of the invention, said method comprising: a) determining the respective expression level of the long-non coding RNAs (IncRNAs) LINC00520 and LINC00518, in a melanoma tumor sample; b) comparing the expression level determined in step a) with a reference expression level for each of said IncRNA, thereby identifying whether the melanoma tumor is suitable for said treatment.
- IncRNAs long-non coding RNAs
- expression level refers herein to the amount or level of said IncRNA expressed in biological sample, such as a cell, tissue, or organ(s), herein preferably melanocytes or skin.
- level refers to an amount (e.g. relative amount or concentration) of a IncRNA that is detectable or measurable in a sample.
- the level can be a relative amount by comparison to a reference expression level.
- the act of actually “determining the expression lever of a IncRNA in a biological sample refers to the act of actively detecting whether the IcnRNA is expressed in said sample or not, and notably allows to detect whether the expression of the IcnRNA is upregulated, downregulated or substantially unchanged when compared to a reference expression level.
- reference expression lever or control expression lever as applied to a IcnRNA, it is meant a predetermined expression level of said IcnRNA, which can be used as a reference in the method of the invention.
- a reference expression level can be the expression level of the IncRNA in a biological sample of a healthy subject, or the average or median expression level in a biological sample of a population of healthy subjects.
- step a) is performed by PCR, such as quantitative PCR (qPCR).
- PCR quantitative PCR
- an increased expression level of LINC00520 in step a) and increased expression level of LINC00518 in step a) is indicative of the suitability of said treatment, especially when the reference expression level is one of a healthy subject or population of heathy subjects.
- the present invention is directed to a kit for use in the in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors, said kit comprising: a) at least one reagent capable of specifically determining the expression level of the long-non coding RNA (IncRNA) LINC00520; and b) at least one reagent capable of specifically determining the expression level of the long-non coding RNA (IncRNA) LINC00518; c) optionally, instructions for performing said method.
- the term “instructions ” refers to a publication, a recording, a diagram, or any other medium which can be used to communicate how to perform a method of the invention.
- Said instructions can, for example, be affixed to a container which contains said kit.
- the instructions for using said kit include the reference expression level for each IncRNA.
- reagent capable of specifically determining the expression lever designates a reagent or a set of reagents which specifically recognizes said IncRNA, and allows for the quantification of the expression level thereof.
- These reagents can be for example nucleotide probes (also known as primers).
- nucleotide probes also known as primers.
- such reagent is said to be “specific” for the IncRNA or “recognizes specifically” the IncRNA if it 1) exhibits a threshold level of hydridization, and/or 2) does not significantly cross-react with other targets.
- the hydridization capacity and cross-reactivity of a reagent can be easily determined by one skilled in the art, and thus need to be further detailed herein.
- the present invention further aims at providing an innovative therapeutic approach for the treatment of melanoma, by inhibiting the functional expression of the melanoma-specific IncRNA LINC00520 and the mitogen-activated protein kinase (MAPK) pathway.
- MAPK mitogen-activated protein kinase
- the present invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 for use in combination with (ii) an inhibitor of the mitogen-activated protein kinase (MAPK) pathway, in the treatment of a melanoma.
- IncRNA long-non coding RNA
- MAPK mitogen-activated protein kinase
- the present invention is directed to the combined use of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of the mitogen-activated protein kinase (MAPK) pathway, for the preparation of a medicament for the treatment of a melanoma.
- an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and
- an inhibitor of the mitogen-activated protein kinase (MAPK) pathway for the preparation of a medicament for the treatment of a melanoma.
- a melanoma in a subject in need thereof, said method comprising the administration, to said subject, of a therapeutically effective amount of:
- a “long-non coding RNA” (long ncRNA, or IncRNA) is generally referred as a non-coding RNA that is at least 200 nucleotides in length.
- a particular class of IncRNA are “long intergenic noncoding RNAs” (lincRNAs), which are sequences of IncRNA transcribed from non-coding DNA sequences between protein-coding genes.
- the terms “LINC00520” , “long intergenic non-protein coding RNA 520”, “C14orf34” or “LASSIE” refer herein to the long intergenic non-protein coding RNA 00520. It is disclosed in the Gene database under ID 645687, in the HGNC database under ID 19843, in the Ensembl database under ID ENSG00000258791.
- the LINC00520gene encodes 12 splicing variants (i.e. isoforms), arising from up to 5 exons (see Table 2’). Unless specified otherwise, the term “IJNC0052(r encompasses all the isoforms thereof.
- LINC00520 isoforms and exons (sequences available on Ensembl database)
- functional expression of a gene, it is meant the transcription and/or translation of functional gene product.
- an “inhibitor of functional expression” of a gene refers to a molecule or technical means capable of decreasing or even abolish the expression of said gene.
- functional expression can be deregulated on at least two levels: first, at the DNA level, e.g. by absence or disruption of the gene, or lack of transcription taking place (in both instances preventing synthesis of the relevant gene product); second, at the RNA level, e.g. by lack of splicing or lack or decrease in the activity mediated by said IncRNA. Inhibition can be evaluated by any means known to those skilled in the art including, but not limited to, assessing the level of IncRNA transcript using e.g. quantitative PCR. Besides, in the context of the present invention, it shall be understood that the inhibitor is selective, or in other words, specific for the targeted IncRNA, in that it does not inhibit, or at least does not substantially inhibit, any other target.
- Such inhibitor is capable of inhibiting the functional expression of the IncRNA in vivo and/or in vitro.
- This inhibitor may inhibit the functional expression of the IncRNA by at least about 10%, 15% 20%, or 25%, preferably by at least about 30%, 35%, 40% or 45%, still preferably by at least about 50%, 55%, 60%, or 65%, yet preferably by at least about 70%, 75%, 80%, or 85%, more preferably by at least about 90%, or 95%.
- an “inhibitor of the MAPK pathway” or “MAPK pathway inhibitor” refers to a molecule or technical means capable of decreasing or even abolish the MAPK pathway.
- the MAPK pathway is a signaling pathway well-known for its involvement in tumorigenesis including cancer cell proliferation, migration, invasion and survival. Inhibition of the MAPK pathway can be measured by conventional methods in the art, such as those described by Amara et al. (Eur J Cancer. 2017; 73:85-92) and/or Fernandez et al. (Cancers 2023, 15(12), 3224).
- the inhibitor of the MAPK pathway may preferably be a BRAF inhibitor, a MEK inhibitor, a C-Kit inhibitor, or any combination thereof.
- a MAPK pathway inhibitor is capable of inhibiting the MAPK pathway in vivo and/or in vitro. This inhibitor may inhibit the MAPK pathway by at least about 10%, 15% 20%, or 25%, preferably by at least about 30%, 35%, 40% or 45%, still preferably by at least about 50%, 55%, 60%, or 65%, yet preferably by at least about 70%, 75%, 80%, or 85%, more preferably by at least about 90%, or 95%.
- treatment means obtaining a desired physiological or pharmacological effect depending on the degree of severity of the symptom or disorder of interest, or risks thereof, i.e. herein, depending on the degree of severity or risks of developing such symptom or disorder.
- this includes, inter alia, the alleviation of symptoms, the reduction of inflammation, the inhibition of cancer cell growth, and/or the reduction of tumor size.
- these terms are intended to encompass curing as well as ameliorating at least one symptom of the condition or disease.
- a response to treatment includes a reduction in cachexia, increase in survival time, elongation in time to tumor progression, reduction in tumor mass, reduction in tumor burden and/or a prolongation in time to tumor metastasis, time to tumor recurrence, tumor response, complete response, partial response, stable disease, progressive disease, progression free survival, overall survival, each as measured by standards set by the National Cancer Institute and the U.S. Food and Drug Administration for the approval of new drugs. See Johnson et al., J. Clin. Oncol., 2009; 21(7): 1404-1411.
- the term treatment refers to the inhibition or reduction of cancer cell proliferation and/or the increase in cancer cell apoptosis in a subject having the cancer, herein melanoma.
- the inhibition or reduction of cancer cells and/or the increase in apoptosis of cancer cells is independent of the status of tumor-associated proteins, herein independent of BRAF and/or NBAS status, more preferably independent to the BRAF status.
- tumor-associated proteins e.g. BRAF status, NRAS status
- melanoma cells cells of interest
- the term is used in the sense “irrespective of or “independent of status, meaning that an effect is observed irrespective of expression levels of, or presence of mutations in, the particular protein in the cells of interest (herein, melanoma cells).
- BRAF mutations are more commonly observed in intermittently sun-exposed skin, and associated with KIT mutations, which are present predominantly in mucosal and acral melanomas.
- BRAF mutations associated with melanoma include, without limitation, R461I, I462S, G463E, G463V, G465A, G465E, G465V, G468A, G468E, N580S, E585K, D593V, F594L, G595R, L596V, T598I, V599D, V599E, V599K, V599R, V600E/K (the most prominent), K600E, A727V, and most of these mutations are clustered to two regions: the glycine-rich P loop of the N lobe and the activation segment and flanking regions.
- the BRAF mutation is V600E/K, preferably V600E.
- NRAS mutations are more commonly observed in older patients (above 55 years-old), with a chronic pattern of UV exposure with lesions are usually located at the extremities.
- Examples of NRAS mutations typically associated with melanoma include, without limitation, G12D/C, G13R, Q61K, Q61R, Q61L, Q61V, Q61H, Q61P.
- the NRAS mutation is Q61K/R.
- a “therapeutically effective amount' means herein an amount that is sufficient to achieve the effect for which it is indicated, herein the treatment of a melanoma.
- the amount of the combination therapy of the invention to be administered can be determined by standard procedures well known by those of ordinary skill in the art. Physiological data of the patient (e.g. age, size, and weight), the routes of administration and the disease to be treated have to be taken into account to determine the appropriate dosage, optionally compared with subjects that do not suffer from a melanoma. The amount may also vary according to other components of a treatment protocol (e.g. administration of other medicaments, etc.).
- a “subtherapeutic amount” or “subtherapeutic dose” is an amount that is not therapeutically effective if administered in absence of any other agent or therapy.
- the “subject” or “patients” to be treated according to the invention is one having an integumentary system. Accordingly, preferred subjects to be treated are animals, more preferably mammals, most preferably humans.
- melanoma also known as “malignant melanoma”, refers to a type of cancer that develops from the pigment-producing cells called melanocytes.
- melanocytes There are three main categories of melanoma: cutaneous melanoma, the most common, which corresponds to the melanoma of the skin; mucosal melanoma which can affect any mucous membrane of the body, including the nasal passages, throat, vagina, anus, or mouth; and ocular melanoma, which is a rare form of melanoma affecting the eye (also known as uveal or choroidal melanoma).
- the melanoma to be treated can be at any stage.
- the melanoma can be at stage VII, II, III, or IV, preferably stage II, III, or IV, more preferably stage III, or IV.
- the melanoma can be at stage Tla, Tib, T2a, T2b, T3a, T4a, T4b, Nl, N2, N3, Mia, Mlb, or Mlc, preferably stage T2b, T3a, T4a, T4b, Nl, N2, N3, Mia, Mlb, or Mlc.
- the melanoma is at an advanced or metastatic stage.
- the melanoma can be preferably selected from the group consisting of lentigo maligna, lentigo maligna melanoma, superficial spreading melanoma, acral lentiginous melanoma, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, melanoma with small nevus-like cells, melanoma with features of a Spitz nevus, uveal melanoma, Harding-Passey melanoma, juvenile melanoma, amelanotic melanoma, Cloudman’s melanoma, and vaginal melanoma.
- the melanoma is a melanocytic melanoma.
- the melanoma is a cutaneous or ocular (e.g. uveal) melanoma.
- the melanoma is a cutaneous or ocular (e.g. uveal) melanocytic melanoma.
- resistant melanoma refers to a melanoma, which does not respond to a conventional treatment for said cancer.
- the cancer may be resistant at the beginning of treatment or it may become resistant during treatment or does not respond anymore. The resistance to the treatment may lead to rapid progression of metastatic of melanoma.
- the melanoma can be resistant to a targeted therapy, especially inhibitors of the MAPK pathway which include BRAF inhibitors, MEK inhibitors and C-Kit inhibitors; to chemotherapy; and/or to immune checkpoint inhibitors.
- the melanoma is resistant to a targeted therapy, especially BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib, and/or MEK inhibitors, such as trametinib, cobimetinib, binimetinib, or selumetinib; or a combination thereof such as to the dabrafenib/ trametinib (DT) combination.
- BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib
- MEK inhibitors such as trametinib, cobimetinib, binimetinib, or selumetinib; or a combination thereof such as to the dabrafenib/ trametinib (DT) combination.
- the inhibitor of functional expression according to the invention may indeed restore or increase the sensitivity of melanoma to this type of therapy.
- the melanoma may preferably not be resistant to a targeted therapy, especially inhibitors of the MAPK pathway which include BRAF inhibitors, MEK inhibitors and C-Kit inhibitors; to chemotherapy; and/or to immune checkpoint inhibitors.
- inhibitors of the MAPK pathway which include BRAF inhibitors, MEK inhibitors and C-Kit inhibitors; to chemotherapy; and/or to immune checkpoint inhibitors.
- the melanoma is not resistant to a targeted therapy, especially BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib; and/or MEK inhibitors such as trametinib, cobimetinib, binimetinib, or selumetinib; or a combination thereof such as to the dabrafenib/ trametinib (DT) combination.
- BRAF inhibitors such as dabrafenib, vemurafenib, or encorafenib
- MEK inhibitors such as trametinib, cobimetinib, binimetinib, or selumetinib; or a combination thereof such as to the dabrafenib/ trametinib (DT) combination.
- the inhibitor of functional expression according to the invention may indeed prevent, decrease or delay the appearance of a resistance to such therapy.
- the melanoma can be associated with a BRAF mutation and/or with a NRAS mutation, as described above.
- the inhibitors of functional expression according to the invention may indeed act independently of BRAF and/or NRAS status, as explained above.
- the present invention requires the inhibition of the melanoma-specific IncRNA LINC00520.
- Inhibitors of functional expression of LINC00520 have been reported in the scientific and patent literature (Luan et al., Journal of Experimental & Clinical Cancer Research 2020, 39:96; Huang et al., BMC Pulm Med 2021, 21 :287; the contents of which are incorporated herein by reference in their entireties). Below is provided a non-exhaustive list of such inhibitors which can be used in the present invention.
- the inhibitor of functional expression used in the present invention can preferably be either a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA, or a genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA.
- a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA might be preferred should one wish to inhibit functional expression at the RNA level, while a genome editing system comprising a nuclease engineered to target specifically the long-non coding RNA might be preferred should one wish to inhibit functional expression at the DNA level.
- the inhibitor used in the present invention can be a nucleic acid molecule interfering specifically with the expression of the long-non coding RNA.
- nucleic acid molecule refers to a succession of natural or synthetic nucleotides (or nucleosides) connected by intemucleotide (or intemucleoside) linkages, wherein each nucleotide (or nucleoside) or internucleotide (or intemucleoside) linkages may be modified or unmodified.
- a nucleotide is comprised of a nucleoside and a phosphate group.
- a nucleoside is comprised of a nucleobase and a sugar.
- a nucleobase comprises a modified and unmodified nucleobase.
- Unmodified nucleobases are well-known in the art and include adenine (A), thymine (T), cytosine (C), uracil (U) and guanine (G).
- An internucleotide (intemucleoside) linkage is a bond that forms a covalent linkage between adjacent nucleotides (nucleosides) in a nucleic acid, such as phosphate intemucleotide linkages that are naturally occurring.
- a nucleic acid may be a single-stranded or double-stranded DNA such as cDNA, genomic DNA, ribosomal DNA, and the transcription product of said DNA, such as RNA.
- Nucleic acids also encompass nucleic acids which can hybridize to a nucleic acid of reference.
- a nucleic acid When a nucleic acid is designed to hybridize to a nucleic acid of reference, it can be chemically modified to enhance its stability, nuclease resistance, target specificity and/or improve their pharmacological properties (e.g. reduced toxicity, increased intracellular transport, etc.).
- a nucleic acid may comprise modified nucleotide(s) and/or backbone, such as a modified sugar, a modified nucleobase, and/or a modified intemucleotide (intemucleoside) linkage.
- a standard modification is the replacement of native phosphates of the intemucleotide (intemucleoside) linkage with phosphorothioates (PS) so as to reduce the sensitivity to nucleases and accordingly improve the stability, half-life and tissue distribution of the nucleic acid (Eckstein F., Antisense and Nucleic Acid Drug Development, 2000, 10(2): 1117-221).
- PS phosphorothioates
- Preferred nucleic acid molecules interfering specifically with the expression of the long-non coding RNA according to the invention are those capable of hybridizing specifically to the gene or transcripts of the IncRNA, at least to a part thereof; as such, these are usually non-naturally occurring nucleic acids (i.e. synthetic).
- Hybridizing or “hydridization” means the pairing or annealing to a target, herein under physiological conditions, typically via hydrogen bonding between complementary nucleotides, such as Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding.
- a specific hybridization therefore means that the pairing or annealing is specific to the target (no off-targets effects, or at least no substantial off-targets effects).
- M nucleic acid molecule capable of hybridizing to a target nucleic acid thus means that a stretch of this nucleic acid is capable of forming base pairs to another stretch of the target nucleic acid. It is thus not absolutely required that all the bases in the region of complementarity are capable of pairing with bases in the opposing strand. Mismatches may be tolerated to some extent, as long as in the circumstances, the stretch of nucleotides is capable of hybridizing to its complementary part.
- the nucleic acid molecule interfering specifically with the expression of the long-non coding RNA is preferably an antisense nucleic acid, an RNAi nucleic acid, or a ribozyme.
- antisense nucleic acid or “antisense oligonucleotides” (ASO) designates a synthetic single-stranded oligonucleotide of which the sequence is at least partially complementary to a target nucleic acid, such as to the RNA sequence of a target gene (Lee et al., J Cardiovasc Transl Res. 2013; 6(6):969-80; DeVos et al., Neurotherapeutics 2013; 10(3):486-972013).
- An antisense nucleic acid is capable of altering the expression of a specific target gene, either by splicing modification, or by recruiting RNAse H leading to RNA degradation of RNA-DNA duplexes, thus blocking the expression of the target gene.
- An antisense nucleic acid is typically short in length, in general 5 to 50 nucleotides in length, such as 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length, more preferably 10, 15, 20, 25, 30, 35 nucleotides in length. It is well within the skill of the person in the art to design antisense nucleic acids specific to a target, based on the knowledge of a target sequence such as introns, exons, or 5’CAP (DeVos et al., Neurotherapeutics 2013; 10(3):486-972013). Antisense nucleic acids can be prepared by methods well-known in the art, such as by chemical synthesis and enzymatic ligation reactions.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA inhibits the splicing of the pre- long-non coding RNA, or in other words, it inhibits the formation of the mature long-non coding RNA.
- An antisense nucleic acid can indeed be designed to block a splice acceptor (SA) site and/or an exon splicing enhancer (ESE) and/or any sequence which could modulate a pre-RNA splicing, i.e. it can be designed to be complementary to a part of the pre-RNA comprising an SA, an ESE, or any sequence which could modulate its splicing.
- SA splice acceptor
- ESE exon splicing enhancer
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA induces a RNAse H mediated degradation.
- RNAse H is a cellular enzyme which recognizes duplex between DNA and RNA, and enzymatically cleaves the RNA molecules.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA comprises a region that comprises DNA or DNA-like nucleotides complementary to the targeted IncRNA which is responsible for RNAse H recruitment, ultimately leading to the cleavage of the target nucleic acid.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA is complementary to all or part of the IncRNA, preferably to a part thereof, such as any one of its exons or introns. Sequences of LINC00520 are well known in the art, as explained above.
- the antisense nucleic acid interfering specifically with the expression of LINC00520 comprises or consists of a contiguous nucleotide sequence of at least 10 to 30 (preferably 11 to 29, 12 to 26, 13 to 24, 14 to 22, 14 to 17, 14, 15 or 16) nucleotides in length that is complementary to a specific region of the LINC00520 sequence.
- Non limiting examples of such antisense nucleic acids include, without limitation, those comprising or consisting a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 4 or 5, such as those comprising or consisting of the sequence SEQ ID NO: 4 or 5.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA may further comprise at least one modified sugar, at least one modified internucleotide (or internucleoside) linkage, and/or at least one modified nucleobase, so as to enhance its properties, such a reduction in sensitivity to nucleases, increase in stability, half-life and/or tissue distribution, and/or enhancement of its affinity towards its target nucleic acid.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA comprises at least one modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-O-Me), 2’fluoro (2’-F), 2’0- methoxyethyl (2’-M0E also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl).
- a “modified sugar” is a sugar that is non-naturally occurring.
- 2’,4’-brigded which is the introduction of a methylene bridge between the 2’ and 4’ position of the nucleotide, defining locked nucleic acids (LNA), is herein particularly preferred so as to confer or increase the stability of a nucleic acid when hybridized to a complementary DNA or RNA nucleic acid.
- LNA locked nucleic acids
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA comprises at least one modified intemucleotide (or internucleoside) linkage, such as a phosphorothioate intemucleotide (or internucleoside) linkage.
- a “modified internucleotide linkage” is an intemucleotide (or intemucleoside) linkage in a nucleic acid that is non-naturally occurring, and is thus referred as a non-phosphate linkage.
- a phosphorothioate linkage which is a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom, is herein particularly preferred so as to confer or increase the resistance of a nucleic acid to nucleases.
- the antisense nucleic acid interfering specifically with the expression of the long-non coding RNA is a gapmer.
- a “gapmer” refers to a nucleic acid molecule comprising an internal segment having a plurality of nucleotides (or nucleosides) that support RNase H cleavage positioned between external segments, each having one or more nucleotides (or nucleosides), wherein the nucleotide (or nucleosides) comprising the internal segment are chemically distinct from the immediately adjacent nucleotide(s) (or nucleoside(s)) comprising the external segments.
- the internal or central segment may be referred to as the “gap”, “gap segment” or “gap region” (G); while the external segments may be referred to as the “wings”, “flanks”, “wing segments” , “flank segments” , “wing regions” or “flank regions” (F for the 5’ flank region and F’ for the 3’ flank region).
- the F and F’ regions are composed of modified ribonucleotides (RNA*) which are complementary to a target nucleic acid;
- the G region is composed of deoxyribonucleotides, i.e. DNA or DNA-like molecules, which is responsible for RNAse H recruitment which ultimately leads to the degradation of the target nucleic acid.
- Gapmers can typically comprise a gap region (G) of 5 to 15 deoxynucleotides (or deoxynucleosides) flanked by wing regions (F and F’) of 2 to 10 modified nucleotides (or nucleosides) each.
- the gapmer interfering specifically with the expression of the long-non coding RNA comprises or consists of a contiguous nucleotide (or nucleoside) sequence corresponding to the following formula:
- the gapmer interfering specifically with the expression of the long-non coding RNA can comprise or consist of a contiguous nucleotide (or nucleoside) sequence that is complementary to a specific region of the IncNRA sequence and that corresponds to the following formula:
- each wing segment (F or F’) comprises at least 2 to 10 nucleotides (or nucleosides) in length
- each nucleotide (or nucleoside) of each wing segment (F and F’) comprises a modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-0-Me), 2’fluoro (2’-F), 2’O-methoxyethyl (2’-M0E also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl), more preferably 2’,4’-brigded, and wherein each internucleotide (or intemucle
- the gapmer interfering specifically with the expression of LINC00520 comprises or consists of a contiguous nucleotide (or nucleoside) sequence corresponding to the following formula:
- each wing segment (F or F’) comprises at least 2 to 10 nucleotides (or nucleosides) in length
- each nucleotide (or nucleoside) of each wing segment (F and F’) comprises a modified sugar, in particular in position 2’ of the nucleotide (or nucleoside) such as 2’-O-methyl (2’-0-Me), 2’fluoro (2’-F), 2’O-methoxyethyl (2’-M0E also known as MOE), 2’,4’-brigded, or cEt (constrained ethyl), more preferably 2’,4’-brigded,
- Non limiting examples of gapmers interfering specifically with the expression of LINC00520 include, without limitation, gapmers comprising or consisting of any one of the following sequences:
- Tbs Tbs Tbs dGs dAs dTs dGs dAs dGs dTs dGs dAs dGs Tbs Cbs Gb (SEQ ID NO: 12)
- Gbs Abs Gbs dTs dmCs dGs dmCs dTs dGs dAs dGs dAs Tbs Tbs Ab (SEQ ID NO: 13) wherein A is an adenine, mC is a 5-methylcytosine, G is a guanine, T is a thymine, b is LNA (2',4'-methylene bridged sugar moiety), d is a 2’ -deoxyribosyl sugar moiety, and s is a phosphorothioate intemucleotide (or intemucleoside) linkage.
- RNAi can be used to inhibit the functional expression of the IncRNA.
- RNAi nucleic acid refers to a nucleic acid that can inhibit expression of a target gene by RNA interference (RNAi) mechanism. By contrast to antisense nucleic acids, RNAi nucleic acids target mature RNA. RNAi nucleic acids are well-known in the art, and include short-hairpin RNA (shRNA), small interfering RNA (siRNA), double-stranded RNA (dsRNA), and single-stranded RNA (ssRNA) (Sohail et al. 2004, Gene Silencing by RNA Interference: Technology and Application 1 st Edition, ISBN 9780849321412; WO 99/32619; Wang et al., Pharm Res 2011, 28:2983-2995).
- shRNA short-hairpin RNA
- siRNA small interfering RNA
- dsRNA double-stranded RNA
- ssRNA single-stranded RNA
- RNA interference designates a phenomenon by which dsRNA specifically suppresses expression of a target gene at post-transcriptional level.
- dsRNA double-stranded RNA molecules
- siRNA short interfering RNA
- RISC another enzyme
- the siRNAs that are naturally produced by Dicer are typically 21-23 bp in length, with a 19 or 20 nucleotides duplex sequence, two-nucleotide 3' overhangs and 5'-triphosphate extremities (Zamore et al. Cell. 2000,101(l):25-33; Elbashir et al. Genes Dev. 2001, 15(2): 188-200; Elbashir et al. EMBO J. 2001, 20(23):6877-88).
- the selected siRNA or shRNA target sequence should be subjected to a BLAST search against EST database to ensure that the only desired gene is targeted.
- RNAi nucleic acid can be of at least about 10 to 40 nucleotides (or nucleosides) in length, preferably about 15 to 30 base nucleotides (or nucleosides) in length.
- siRNA or shRNA can comprise naturally occurring RNA, synthetic RNA, or recombinantly produced RNA, as well as altered RNA that differs from naturally- occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides (or nucleosides).
- Such alterations can include addition of non-nucleotide (or non-nucleoside) material, such as to the end of the molecule or to one or more internal nucleotides (or nucleoside) of the RNAi, including modifications that make the RNAi resistant to nuclease digestion, as described above.
- non-nucleotide (or non-nucleoside) material such as to the end of the molecule or to one or more internal nucleotides (or nucleoside) of the RNAi, including modifications that make the RNAi resistant to nuclease digestion, as described above.
- the nucleic acid molecule interfering specifically with functional expression of the IncRNA is an RNAi nucleic acid, that is complementary to at least one part of the IncRNA, in particular to at least one exon thereof
- the RNAi nucleic acid can be a siRNA or shRNA of at least about 10 to 40 nucleotides (or nucleosides) in length, preferably of about 15 to 30 nucleotides (or nucleosides) in length.
- the RNAi nucleic acid interfering specifically with the expression of LINC00520 comprises or consists of a contiguous nucleotide sequence of at least 10 to 40 (preferably 15 to 30, 16 to 25, 17 to 24, 20, 21, 22 or 23) nucleotides in length that is complementary to a specific region of the LINC00520 sequence.
- Non limiting examples of such RNAi nucleic acid include, without limitation, those comprising or consisting of a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 23, preferably those comprising or consisting of the sequence SEQ ID NO: 23.
- the nucleic acid interfering specifically with the functional expression of the IncRNA is a ribozyme.
- Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Ribozyme molecules specific for a target (herein a IncRNA) can be designed, produced, and administered by methods commonly known to the art (see e.g., Fanning and Symonds (2006) RNA Towards Medicine (Handbook of Experimental Pharmacology), ed. Springer p. 289-303).
- the nucleic acid molecule interfering specifically with the functional expression of LINC00520 is a ribozyme targeting said IncRNA.
- genome editing can be used to inhibit the functional expression of the IncRNA. More specifically, one can use a genome editing system comprising a nuclease engineered to target the IncRNA gene.
- Gene editing is a type of genetic engineering in which DNA is inserted, replaced, or removed from a genome using artificially engineered nucleases, also called molecular scissors. Nucleases create specific double-stranded break (DSBs) at desired locations in the genome, and harness the cell's endogenous mechanisms to repair the induced break by natural processes of homologous recombination (HR) or non-homologous end-joining (NHEJ).
- HR homologous recombination
- NHEJ non-homologous end-joining
- ZFNs zinc finger nucleases
- TALENs transcription activator-like effector nucleases
- Cas9 the CRISPR/Cas system in particular the Cas9 system
- engineered meganucleases re-engineered homing endonucleases.
- Said nucleases can be delivered to the cells either as DNAs or mRNAs, such DNAs or mRNAs and can be engineered to target the IncRNA gene.
- a particularly preferred genome editing system according to the invention is the CRISPR/Cas system in particular the Cas9 system.
- the genome editing system interfering specifically with functional expression of LINC00520 is a CRISPR/Cas system, in particular a CRISPR/Cas9 system, targeting said IncRNA.
- sgRNA single guide RNA
- Non limiting examples of such sgRNA include, without limitation, those comprising or consisting of a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 19, 20 or 21, preferably those comprising or consisting of the sequence SEQ ID NO: 19, 20 or 21, or any combination thereof.
- the genome editing system is a triplet-target CRISPR system, meaning that three guide RNA are used to target LINC00520, such as those described above.
- the present invention further requires the inhibition of the MAPK pathway.
- Inhibitors of the MAPK pathway have been reported in the scientific and patent literature, and include BRAF inhibitors, MEK inhibitors and/or C-Kit inhibitors, which can be useful for treating melanoma.
- the (ii) inhibitor of the mitogen-activated protein kinase (MAPK) pathway is a BRAF inhibitor, a MEK inhibitor, a C-Kit inhibitor, or any combination thereof; preferably is a BRAF inhibitor, a MEK inhibitor or a combination thereof.
- BRAF inhibitors are well known in the art. They have notably been described in e.g. WO 2005/062795, WO 2007/002325, WO 2007/002433, WO 2008/079903, and WO 2008/079906, the disclosure thereof being incorporated by reference in its entirety.
- the inhibitor of BRAF can be vemurafenib or other inhibitors as disclosed in US8470818, US8470818, US8143271, US7863288, US9447089, US7504509 or US8741920, the disclosure thereof being incorporated by reference in its entirety.
- Vemurafenib also known as PLX4032, RG7204 or R05185426 and commercialized by Roche as zelboraf.
- the inhibitor of BRAF can be Dabrafenib also known as tafinlar, which is commercialized by Novartis.
- Other inhibitors of BRAF can be encorafenib, or also LGX818 (Novartis), TAK-632 (Takeda), MLN2480 (Takeda/Millennium), or PLX-4720 (Plexxikon).
- the BRAF inhibitor is dabrafenib, vemurafenib, or encorafenib, or any combination thereof.
- MEK inhibitors are also well known in the art.
- the inhibitor of MEK can be Trametinib also known as mekinist, which is commercialized by GSK.
- the inhibitor of MEK can be Cobimetinib also known as cotellic commercialized by Genentech.
- the inhibitor of MEK can be Binimetinib also known as MEK162, ARRY-162 is developed by Array Biopharma.
- Other MEK inhibitors can be AZD6244 (AstraZeneca/ Array BioPharma), R05126766 (Roche/Chugai), GDC- 0623 (Genentech/Chugai), PD0325901 (Pfizer), and Selumetinib.
- the MEK inhibitor is trametinib, cobimetinib, binimetinib, selumetinib, or any combination thereof.
- the MAPK inhibitor is a combination of BRAF inhibitor and a MEK inhibitor, such as a combination of dabrafenib and trametinib.
- Example 1 described below notably provides evidence that the combination of the ASO targeting LINC00520 with a combination of a BRAF inhibitor and a MEK inhibitor act in a synergistic manner to increase the apoptosis of melanoma cells, even at suboptimal dose.
- any one of the (i) inhibitors of functional expression of the long-non coding RNA (IncRNA) LINC00520, and any one of the (ii) inhibitors of the MAPK pathway, as described herein, can be combined for the purpose of the present invention.
- the inhibitor of functional expression of the long- non coding RNA (IncRNA) LINC00520 is a nucleic acid molecule interfering specifically with the expression of said IncRNA, as described above; and (i) the inhibitor of the MAPK pathway is a BRAF inhibitor, a MEK inhibitor, a C-Kit inhibitor, or any combination thereof, as described above.
- nucleic acid molecule interfering specifically with the expression of LINC00520 is an antisense nucleic acid, as described above; and (ii) the inhibitor of the MAPK pathway is a BRAF inhibitor, a MEK inhibitor, or any combination thereof, as described above.
- the nucleic acid molecule interfering specifically with the expression of LINC00520 can be an antisense nucleic acid comprising or consisting a contiguous nucleotide sequence of at least 10 nucleotides in length of the sequence SEQ ID NO: 4 or 5, such as an antisense nucleic acid comprising or consisting of the sequence SEQ ID NO: 4 or 5; and
- the BRAF inhibitor is dabrafenib, vemurafenib, or encorafenib, or any combination thereof, and/or the MEK inhibitor is trametinib, cobimetinib, binimetinib, selumetinib, or any combination thereof.
- the antisense nucleic acid interfering specifically with the expression of LINC00520 is a gapmer as described above, such as an LNA gapmer which may comprise phosphothiorate linkages; and (ii) the BRAF inhibitor is dabrafenib and/or the MEK inhibitor is trametinib, as described above.
- the gapmer interfering specifically with the expression of LINC00520 can comprise or consist of any one of the following sequences: Tbs Tbs Tbs dGs dAs dTs dGs dAs dGs dTs dGs dAs dGs Tbs Cbs Gb (SEQ ID NO: 12), or Gbs Abs Gbs dTs dmCs dGs dmCs dTs dGs dAs dGs dAs dAs Tbs Tbs Ab (SEQ ID NO: 13); and (ii) the MAPK inhibitor can be a combination of dabrafenib and a trametinib.
- inhibitors of the functional expression of the IncRNAs LINC00520 and (ii) inhibitors of the MAPK pathway can also be envisioned, such as: (i) a genome editing system comprising a nuclease engineered to target specifically LINC00520, as described above and (ii) a BRAF inhibitor, a MEK inhibitor, a C-Kit inhibitor, or any combination thereof, as described above.
- any one of the (i) inhibitors of functional expression of the long-non coding RNA (IncRNA) LINC00520, and any one of the (ii) inhibitors of the MAPK pathway, as described herein, can be further combined with an additional therapy, especially one that is suited for melanoma.
- an additional therapy especially one that is suited for melanoma. This includes, without limitation, surgery, radiotherapy, chemotherapy, other targeted therapy or immune checkpoint therapy, or any combination thereof.
- Such therapies are well-known in the art, and therefore need not be detailed herein.
- the combination of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of the MAPK pathway, as described herein, may be suitable for administration to a cell, tissue and/or an organ of individuals affected by or at risk of suffering from a melanoma, and may be administered in vivo, ex vivo or in vitro. Since melanoma affects melanocytes, it is preferred that said cells are melanocytes, and/or that said tissue or organ is the skin or the eye.
- each inhibitor can be delivered as it is to the subject, or be formulated to be compatible with their intended route of administration.
- the combination can be formulated in a combined pharmaceutical composition, or in separate pharmaceutical compositions, in a form suitable for parenteral, oral, transdermal or topical or intraocular administration, such as a liquid suspension, a solid dosage form (granules, pills, capsules or tablets), or a paste or gel.
- parenteral administration such as subcutaneous, intradermal, intravenous; transdermal administration; topical administration; or even intraocular administration.
- compositions according to the invention may notably be formulated to release the combination therapy immediately upon administration or at any predetermined time or time period after administration.
- the combination When formulated within a pharmaceutical composition, the combination can be further combined with a pharmaceutically acceptable excipient.
- a “pharmaceutically acceptable excipient” means an inactive or inert, and therefore nontoxic, component, as it has no pharmacological action itself, which can be used to improve properties of a composition, such as shelf-life, retention time at the application site, consumer acceptance, etc. It includes, without limitation, surfactants (cationic, anionic, or neutral); surface stabilizers; other enhancers, such as preservatives, wetting or emulsifying agents; solvents; buffers; salt solutions; dispersion medium; isotonic and absorption delaying agents, and the like; that are physiologically compatible.
- the combination therapy is provided in a therapeutically effective amount so as to treat the melanoma.
- the amount of each inhibitor is a pediatric dose in monotherapy, or a dose that is subtherapeutic in monotherapy (yet, is such that it is therapeutically effective in the combination therapy of the invention).
- the amount of each inhibitor is a subtherapeutic dose (yet, is such that it is therapeutically effective in the combination therapy of the invention).
- the present invention relates to (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520, and (ii) an inhibitor of the MAPK pathway, as described above, as a combined preparation for simultaneous, separate or sequential use in the treatment of a melanoma.
- IncRNA long-non coding RNA
- the invention relates to the simultaneous, separate or sequential use of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of the MAPK pathway, as described above, for the preparation of a medicament for the treatment of a melanoma.
- a method for treating a melanoma comprising the simultaneous, separate or sequential administration, to said subject, of a therapeutically effective amount of (i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of the MAPK pathway, as described above.
- a therapeutically effective amount of i) an inhibitor of functional expression of the long-non coding RNA (IncRNA) LINC00520 and (ii) an inhibitor of the MAPK pathway, as described above.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising
- the invention pertains to an in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors of the invention, said method comprising: a) determining, in a melanoma tumor sample, (i) the expression level of the long-non coding RNA (IncRNA) LINC00520, and (ii) the response to (ii) an inhibitor of the mitogen-activated protein kinase (MAPK) pathway; b) comparing the expression level determined in step a) with a reference expression level for said IncRNA, and comparing the response determined in step a) with a reference response to said inhibitor, thereby identifying whether the melanoma tumor is suitable for said treatment.
- a determining, in a melanoma tumor sample determining, in a melanoma tumor sample, (i) the expression level of the long-non coding RNA (IncRNA) LINC00520, and (ii) the response to (ii) an inhibitor of the mitogen-
- expression level refers herein to the amount or level of said IncRNA expressed in biological sample, such as a cell, tissue, or organ(s), herein preferably melanocytes or skin.
- level refers to an amount (e.g. relative amount or concentration) of a IncRNA that is detectable or measurable in a sample.
- the level can be a relative amount by comparison to a reference expression level.
- the act of actually “determining the expression lever of a IncRNA in a biological sample refers to the act of actively detecting whether the IcnRNA is expressed in said sample or not, and notably allows to detect whether the expression of the IcnRNA is upregulated, downregulated or substantially unchanged when compared to a reference expression level.
- reference expression lever or control expression lever as applied to a IcnRNA, it is meant a predetermined expression level of said IcnRNA, which can be used as a reference in the method of the invention.
- a reference expression level can be the expression level of the IncRNA in a biological sample of a healthy subject, or the average or median expression level in a biological sample of a population of healthy subjects.
- the expression level is performed by PCR, such as quantitative PCR (qPCR).
- PCR quantitative PCR
- response means herein that said tumor is either “resistant' to the therapy or “non-resistant” thereto, as described above.
- a reference response as applied to a tumor sample subjected to a cancer therapy, it is meant a predetermined response of a tumor sample of the same tissue to that therapy, which can be used as a reference in the method of the invention.
- a reference response can be the response in a biological sample of a diseased subject, or the average or median reference response in a biological sample of a population of diseased subjects.
- the response can be determined by performing an apoptosis assay and/or proliferation assay on the tumor sample.
- an increased expression level of LINC00520 in step a) and non- resistance to the inhibitor of the MAPK pathway in step a) is indicative of the suitability of said treatment, especially when the reference expression level is one of a healthy subject or population of heathy subjects.
- the invention relates to a kit for use in the in vitro method for identifying a melanoma tumor suitable for treatment with the inhibitors, said kit comprising: a) at least one reagent capable of specifically determining the (i) expression level of the long-non coding RNA (IncRNA) LINC00520; and b) at least one reagent capable of determining (ii) the response to an inhibitor of the mitogen-activated protein kinase (MAPK) pathway; c) optionally, instructions for performing said method.
- a reagent capable of specifically determining the (i) expression level of the long-non coding RNA (IncRNA) LINC00520
- c) optionally, instructions for performing said method.
- the term “instructions” refers to a publication, a recording, a diagram, or any other medium which can be used to communicate how to perform a method of the invention.
- Said instructions can, for example, be affixed to a container which contains said kit.
- the instructions for using said kit include the reference expression level for the IncRNA and/or the reference response to the inhibitor of the MAPK pathway.
- reagent capable of specifically determining the expression lever designates a reagent or a set of reagents which specifically recognizes said IncRNA, and allows for the quantification of the expression level thereof.
- These reagents can be for example nucleotide probes (also known as primers).
- nucleotide probes also known as primers.
- such reagent is said to be “specific” for the IncRNA or “recognizes specifically” the IncRNA if it 1) exhibits a threshold level of hydridization, and/or 2) does not significantly cross-react with other targets.
- the hydridization capacity and cross-reactivity of a reagent can be easily determined by one skilled in the art, and thus need to be further detailed herein.
- reagent capable of determining the response designates a reagent or a set of reagents which can quantify the response thereto.
- reagents are well-known in the art, and thus need not be further detailed herein.
- MM011, MM117, MM047, MM099 were grown in HAM-F10 medium supplemented with 10% FCS, 5.2 mM glutamax, 25 mM Hepes and penicillin/streptomycin (7.5 ug/ml).
- M229, M229R, M249, M249R were grown in DMEM medium supplemented with glucose (4.5 g/1), 5% FCS and penicillin/streptomycin (7.5 ug/ml).
- HEK293T cells were grown in DMEM medium supplemented with glucose (lg/1), 10% FCS and penicillin/streptomycin (7.5 ug/ml).
- GapmeR knockdown experiments cells were transfected using Lipofectamine RNAiMAX (Invitrogen) with 20 nM of GapmeR (Qiagen) and harvested 48 or 72 hours as indicated.
- GapmeR GapmeR
- combination GapmeR experiments cells were transfected with 15nM of LINC00518 GAP#2 and/or LINC00520 GAP#2, using control GapmeR to obtain a constant 30 nM in each transfection.
- RNAs for LINC00520 and MITF were detected with the RNAscope assay (Advanced Cell Diagnostics, ACD, Hayward, CA) according to the manufacturer’s protocols. Briefly, patient sections were de-paraffinized, incubated with hydrogen peroxide at room temperature for 10 min, boiled with target retrieval reagent for 15 min, and then treated with protease plus reagent at 40°C for 30 min. The sections were hybridized with Hs-MITF probe (ACD, Cat. No. 310951), or custom designed LINC00520 probe. Hybridization signals were amplified and visualized with RNAscope Multiplex Fluorescent Reagent Kit v2 (ACD, Cat. No. 323100). Images were captured with a confocal (Leica DMI6000) microscope.
- Total mRNA isolation was performed using Trizol and isopropanol precipitation. Total was treated with DNAsel following the TurboDnase free kit instructions (Thermofisher) and reversed transcribed using Superscript IV reverse transcriptase (Thermofisher) following manufacturer instructions. qRT-PCR was carried out with SYBR Green I (Roche) and monitored by a LightCycler 480 (Roche). Target gene expression was normalized using TBP, HBMS, GAPDH, ACTB, RPL13A as reference genes.
- 501Mel cells were grown in 15cm petri dishes, harvested by trypsinization, washed, pelleted, re-suspended in lysis buffer (TrisHCl 20mM pH8, NaCl 200mM, MgC12 2.5mM, Triton 0.05%, DEPC water) supplemented with fresh DTT (ImM), protease and phosphatase inhibitor cocktail (Thermofisher) and RNAsin (Thermofisher) and kept 20 minutes on ice.
- lysis buffer TrisHCl 20mM pH8, NaCl 200mM, MgC12 2.5mM, Triton 0.05%, DEPC water
- DTT protease and phosphatase inhibitor cocktail
- RNAsin Thermofisher
- LSDB 500 buffer 500 mM KC1, 25 mM Tris at pH 7.9, 10% glycerol (v/v), 0.05% NP-40 (v/v), 16mM DTT, and protease inhibitor cocktail. Lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS- PAGE) and proteins were transferred onto a nitrocellulose membrane. Membranes were incubated with primary antibodies in TBS+ 5% BSA + 0.01% Tween-20. Overnight at 4 °C. The membrane was then incubated with HRP -conjugated secondary antibody (Jackson ImmunoResearch) for Ih at room temperature, and visualized using the ECL detection system (GE Healthcare).
- HRP -conjugated secondary antibody Jackson ImmunoResearch
- 501Mel cells were transduced with lentiviruses expressing either a Doxycycline-inducible control shRNA or a LINC00520 targeting shRNA (see annex below). Each cell line was grown in 15cm petri dishes and treated for 48 hours Doxycycline with before harvesting and preparation of cytoplasmic protein extracts as described above. For immunoprecipitation, extracts were precleared for 1 hour at 4°C with protein G magnetic beads. Lysate was quantified by Bradford protein quantification assay (Biorad) and incubated overnight at 4°C with anti-DHX36a antibody (13159-1-AP Proteintech) or control IgG.
- RNA-protein complexes were added for 3 hours at 4°C to isolate RNA-protein complexes and washed 5 times in lysis buffer. After final wash RNA was purified by Trizol and isopropanol precipitation and proteins eluted by boiling beads in Laemli sample buffer. Immunoprecipitation and subsequent RNA-seq was performed in 3 biological replicates. Briefly, ccomplementary DNA was generated and subjected to ribo-depletion with Ribo-Zero Plus kit and the library prepared using the llumina Stranded Total RNA Prep Ligation before sequencing on an Illumina Hi-Seq2000. Analyses was performed by using the Wald test for differential expression and implemented in the Bioconductor package DESeq2 version 1.16.1.
- RNA showing differential association with DHX36 in control shRNA lines versus LINC00520 shRNA lines were defined as genes with log2(FoldChange) >1 or ⁇ -l and adjusted - value ⁇ 0.05.
- Mitochondria were isolated with the Mitochondria Isolation kit (Thermofisher) following manufacturer instructions. Harvested cells were washed and pelleted, resuspended in buffer A and incubated 2 minutes on ice. Buffer B was added for 5 minutes, vortexing every minute and diluted with buffer C. Nuclei were pelleted 10 minutes at 700g and supernatant centrifuged for 15 minutes at 3000g. Purified mitochondria were washed once in buffer C and used for RNA (Trizol- isopropanol precipitation) or protein (TBS+CHAPS 2%) extraction. Table 3. Gapmers, shRNA and primers used in the present invention
- LINC00520 displayed very low expression (>0.15 TPM) in several normal tissues with highest expression in oesophageal mucosa (Figure 2B).
- LINC00520 showed highest expression in cutaneous melanoma (40-250 TPM, thus more than 100-fold greater than in normal tissues), but lower expression in uveal melanoma and was expressed at low levels in several other tumour types (Figure 2C).
- Figure 2D RNAscope confirmed the absence of LINC00520 expression in keratinocytes, its low expression in normal MITF-expressing melanocytes with much higher expression in primary melanoma ( Figure 2E).
- Uveal melanoma is a highly aggressive form of melanoma. While overall LINC00520 expression was lower in uveal melanoma than in cutaneous melanoma ( Figures 2A-C), reanalyses of single cell RNA-sequencing data from a collection of uveal melanoma tumors published by Pandiani et al. (Cell Death Differ. 2021;28(6): 1990-2000) revealed one uveal melanoma tumor with LINC00520 expression that further displayed poor patient outcome (Figures 4A-B).
- RNA from a collection of melanocytic and de-differentiated/mesenchymal lines showed that LINC00520 was highly expressed in melanocytic cell lines, irrespective of driver mutation, but to trace levels in MM099 and MM047 and absent in Vemurafenib-resistant SK-MEL-25R and M229R or MM029, all of which were of the de-differentiated cell state (Figure 5A).
- GapmeRs locked nucleic acid oligonucleotides
- CTR control non-targeting GapmeR
- LINC00520 promotes melanoma cell proliferation and metastasis via competitive binding to miR-125b-5 which in turn promotes Eukaryotic initiation factor 5A2 (EIF5A2) expression (Luan et al., J Exp Clin Cancer Res. 2020;39(l):96).
- EIF5A2 Eukaryotic initiation factor 5A2
- LINC00520 was expressed in melanocytic cells (MM074, MM074VR, 501Mel, Mel 888), miR-125b-5p was expressed only in mesenchymal type cells that do not express LINC00520 (MM074R, MM047, MM047R, MM099 ( Figure 7A). Moreover, no association of EIF5A2 levels was observed with patient outcome, contrary to LINC00520 ( Figure 7B). These data are incompatible with a mechanism where LINC00520 drives a miR-125b-5p EIF5A2 axis in melanoma. LINC00520 must therefore act in a mechanism independent of miR-125b-5p.
- LINC00520 To identify the real mechanism of action of LINC00520 in melanoma, the Inventors used a set of biotinylated oligonucleotides complementary to LINC00520 to purify it from 501Mel melanoma cells using oligonucleotides complementary to LincRNA PCA3, not expressed in melanoma cells, as a negative control. Proteins that were enriched after LINC00520 purification compared to PCA3 were determined by mass-spectrometry and confirmed by immunoblot analyses. The major enriched protein identified in this experiment was the RNA helicase DHX36.
- DHX36 was strongly enriched by LINC00520 pulldown compared to PC A3 in both native conditions and after UV protein RNA crosslinking (Figure 8A).
- the Inventors performed LINC00520 pulldown in HET293T cells ectopically expressing LINC00520, a cell line with no endogenous expression of this lincRNA.
- DHX36 was selectively captured in HEK293T cells expressing LINC00520 but not in the control GFP-expressing cells ( Figure 8B).
- LINC00520 does not interact with CARF or RAP2, which are the respective effector proteins of the melanoma-specific lincRNAs SAMMSON (Vendramin et al., Nat Struct Mol Biol. 2018;25(11): 1035-1046) and LINC00518 (Gambi et al., Cancer Res. 2022;82(24):4555- 4570) (Figure 8A).
- LINC00520 interacts selectively with DHX36 indicating, which is a completely distinct mechanism of action from those described for SAMMSON or LINC00518.
- the Inventors examined the intracellular localization of LINC00520 and its DHX36 effector protein. Biochemical purification of the cytosol and mitochondria indicated that LINC00520 partitioned between the cytosolic and mitochondrial fractions with mild enrichment in the mitochondrial fraction ( Figure 9A). Similarly, immunoblot analyses indicated that DHX36 was also mildly enriched in the mitochondrial fraction whose purity was confirmed using the mitochondrial specific protein p32 ( Figure 9B).
- DHX36 is an RNA helicase that unwinds G4 quadruplex structures in RNA molecules facilitating their homeostasis and translation.
- LINC00520 regulates association of mRNAs with DHX36 and their translation
- the Inventors immunoprecipitated DHX36 from 501 Mel melanoma cells (N 3) expressing a control shRNA or an shRNA targeting LINC00520.
- the DHX36-associated RNAs were identified by RNA sequencing and RNA displaying differential association with DHX36 identified using DESEQ2 software. 260 RNAs showed reduced association with DHX36 after LINC00520 silencing, whereas 131 showed increased association ( Figure 10A).
- RNAs for UBE4A or RBPJ showed prominent differential association with DHX36.
- the Inventors performed immunoblots on extracts from cells transfected with control or LINC00520 targeting GapmeR. UBE4A protein levels were down-regulated following LINC00520 silencing whereas those of RBPJ were increased ( Figure 10B). These results indicate that mRNA whose association with DHX36 are reduced following LINC00520 silencing were less well translated whereas the opposite was seen for mRNAs with increased association.
- LINC00520 acts therefore by regulating protein translation in melanoma cells at least in part through modulating mRNA interaction with DHX36. Its mechanism of action therefore does not involve miR-125b-5p that is not co-expressed with LINC00520 and is distinct from that of the previously described melanoma-specific lincRNAs SAMMSON and LINC00518.
- LINC00518 and LINC00520 were both found to be expressed in melanocytic type melanoma cells, yet act via distinct mechanisms of action (RAP2C and DRP1 for LINC00518 and DHX36 for LINC00520), the Inventors asked if they could cooperate with one another notably in the promotion of melanoma cell proliferation and survival. To do so, experiments were conducted using suboptimal concentrations of GapmeRs for each LincRNA alone or in combination using CTR GapmeR to ensure a constant amount of GapmeR in each condition.
- Combinatorial targeting of LINC00520 and LINC00518, would especially allow the synergistic targeting of melanocytic cells that form the majority of tumors cells and play a crucial role in metastasis, while still also targeting the smaller populations of mesenchymal and neural crest cells via LINC00518.
- melanoma cells are transfected with suboptimal concentrations of shRNA or siRNA for each IncRNA, used either alone or in combination, using a control (CTR) shRNA to ensure a constant amount of sh/siRNA in each condition.
- CTR control
- RNAi nucleic acid targeting LINC00520 from Table 4 Individual and combinatorial inhibition is also performed with an RNAi nucleic acid targeting LINC00520 from Table 4, and the dabrafenib-trametinib combination.
- EXAMPLE 3 A similar experiment to EXAMPLE 1 (double LINC knockdown) is conducted with a different type of IncRNA inhibitors. This time, individual knockdown of LINC00520 or LINC00518, as well as combinatorial knockdown, are performed in a melanoma cell line using vectors encoding the CRISPR/dCAS9-KAPl fusion protein with or without (CTR) sgRNA targeting it to the LINC518 or LINC00520 promoter region.
- CRISPR/dCAS9-KAPl fusion protein with or without (CTR) sgRNA targeting it to the LINC518 or LINC00520 promoter region.
- melanoma cells are co-transfected using Fugene 6 (Promega) with a plasmid expressing dead Cas9 protein fused to the Kruppel-associated box (KRAB) domain-containing KAP1 (dCas9-KAPl) and the red fluorescent protein mScarlet (pX-dCas9-KRAB-Scarlet), together with a plasmid expressing GFP and three single guide RNAs targeting the transcription start site of LINC00518 or LINC00520 or a control plasmid expressing GFP only (pCMV-GFP).
- KRAB Kruppel-associated box
- pX-dCas9-KRAB-Scarlet red fluorescent protein mScarlet
- Double Scarlet-GFP positive cells are sorted 24 hours after co-transfection, stained with Cell Trace Violet and kept in culture for additional 96 hours. Cells are harvested to prepare total RNA and stained with AnnexinV-APC (Biolegend). Cells are analysed on a LSRII Fortessa (BD Biosciences) and data were analysed with Flowjo software (Tree Star).
- RNAi nucleic acid for one IncRNA • a RNAi nucleic acid for one IncRNA, combined with vector encoding the CRISPR/dC AS9- KAP1 fusion protein with sgRNA targeting the promoter region of the other IncRNA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention se rapporte au domaine de l'oncologie. Plus particulièrement, la présente invention concerne une nouvelle polythérapie destinée à être utilisée dans le traitement d'un mélanome.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22305951.0 | 2022-06-30 | ||
EP22305951 | 2022-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024003350A1 true WO2024003350A1 (fr) | 2024-01-04 |
Family
ID=82786574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/067998 WO2024003350A1 (fr) | 2022-06-30 | 2023-06-30 | Polythérapie pour mélanome |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024003350A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032619A1 (fr) | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Inhibition genetique par de l'arn double brin |
WO2005062795A2 (fr) | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Composes et methodes de developpement de modulateurs de ret |
WO2007002433A1 (fr) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Derives de pyrrolo [2, 3-b] pyridine utilises comme inhibiteurs de proteines kinases |
WO2008079903A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Dérivés de pyrrolo [2, 3-b] pyridine utilisés comme modulateurs de kinase |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
WO2021152005A1 (fr) | 2020-01-28 | 2021-08-05 | Universite De Strasbourg | Oligonucléotide antisens ciblant linc00518 pour le traitement du mélanome |
-
2023
- 2023-06-30 WO PCT/EP2023/067998 patent/WO2024003350A1/fr unknown
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032619A1 (fr) | 1997-12-23 | 1999-07-01 | The Carnegie Institution Of Washington | Inhibition genetique par de l'arn double brin |
WO2005062795A2 (fr) | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Composes et methodes de developpement de modulateurs de ret |
US7504509B2 (en) | 2003-12-19 | 2009-03-17 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
WO2007002325A1 (fr) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Composes et methodes de modulation de la kinase et instructions afferentes |
WO2007002433A1 (fr) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Derives de pyrrolo [2, 3-b] pyridine utilises comme inhibiteurs de proteines kinases |
US7863288B2 (en) | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8143271B2 (en) | 2005-06-22 | 2012-03-27 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8470818B2 (en) | 2005-06-22 | 2013-06-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008079903A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Dérivés de pyrrolo [2, 3-b] pyridine utilisés comme modulateurs de kinase |
WO2008079906A1 (fr) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Composés et méthodes pour moduler une kinase et indications associées |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
WO2021152005A1 (fr) | 2020-01-28 | 2021-08-05 | Universite De Strasbourg | Oligonucléotide antisens ciblant linc00518 pour le traitement du mélanome |
Non-Patent Citations (36)
Title |
---|
"Encyclopedia of Pharmaceutical Technology", 1988, MARCEL DEKKER |
"Genbank", Database accession no. NR 027793 |
"Gene", Database accession no. ID 645687 |
"GeneCards", Database accession no. GC06M010428 |
AMARA ET AL., EUR J CANCER, vol. 73, 2017, pages 85 - 92 |
BERNSTEIN ET AL., NATURE., vol. 409, no. 6818, 2001, pages 363 - 6 |
CANCERS, vol. 15, no. 12, 2023, pages 3224 |
DEVOS ET AL., NEUROTHERAPEUTICS, vol. 10, no. 3, 2013, pages 486 - 972013 |
ECKSTEIN F, ANTISENSE AND NUCLEIC ACID DRUG DEVELOPMENT, vol. 10, no. 2, 2000, pages 1117 - 221 |
ECKSTEIN F, ANTISENSE AND NUCLEIC ACID DRUG DEVELOPMENT,, vol. 10, no. 2, 2000, pages 1117 - 221 |
ELBASHIR ET AL., EMBO J, vol. 20, no. 23, 2001, pages 6877 - 88 |
ELBASHIR ET AL., GENES DEV, vol. 15, no. 2, 2001, pages 188 - 200 |
FANNINGSYMONDS: "RNA Towards Medicine (Handbook of Experimental Pharmacology", 2006, SPRINGER, article "RNA Towards Medicine", pages: 289 - 303 |
GAMBI ET AL., CANCER RES, vol. 82, no. 24, 2022, pages 4555 - 4570 |
HUANG ET AL., BMC PULM MED, vol. 21, 2021, pages 287 |
HUANG ET AL., BMC PULM MED,, vol. 21, 2021, pages 287 |
HUANG ET AL.: "21", BMC PULM MED, 2021, pages 287 |
JOHNSON ET AL., J. CLIN. ONCOL, vol. 21, no. 7, 2009, pages 1404 - 1411 |
LEE ET AL., J CARDIOVASC TRANSL RES, vol. 6, no. 6, 2013, pages 969 - 80 |
LUAN ET AL., J EXP CLIN CANCER RES, vol. 39, no. 1, 2020, pages 96 |
LUAN ET AL., JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 39, 2020, pages 96 |
LUAN WENKANG ET AL: "Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis", vol. 39, no. 1, 96, 28 May 2020 (2020-05-28), pages 1 - 16, XP093002496, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s13046-020-01599-7/fulltext.html> DOI: 10.1186/s13046-020-01599-7 * |
MALI ET AL., NATURE METHODS, vol. 10, no. 10, 2013, pages 957 - 63 |
PANDIANI ET AL., CELL DEATH DIFFER, vol. 28, no. 6, 2021, pages 1990 - 2000 |
RAMBOW ET AL., CELL, vol. 174, no. 4, 2018, pages 843 - 855 |
SETH ET AL., J CLIN INVEST, vol. 129, no. 3, 2019, pages 915 - 925 |
SETH ET AL., J CLIN INVEST., vol. 129, no. 3, 2019, pages 915 - 925 |
SOHAIL ET AL.: "ISBN 9780849321412", 2004, article "Gene Silencing by RNA Interference: Technology and Application" |
VENDRAMIN ET AL., NAT STRUCT MOL BIOL, vol. 25, no. 11, 2018, pages 1035 - 1046 |
WANG ET AL., PHARM RES, vol. 28, 2011, pages 2983 - 2995 |
WATTS ET AL., J PATHOL, vol. 226, no. 2, 2012, pages 365 - 379 |
WATTS ET AL., J PATHOL., vol. 226, no. 2, 2012, pages 365 - 379 |
WOZNIAK MICHAL ET AL: "The Functional Role of Long Non-Coding RNAs in Melanoma", vol. 13, no. 19, 4848, 2021, pages 1 - 30, XP055972159, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508152/pdf/cancers-13-04848.pdf> DOI: 10.3390/cancers13194848 * |
XU JIE ET AL: "LINC00518 affects the proliferation, invasion and migration of cutaneous malignant melanoma cells via miR-526b-3p/EIF5A2 axis", ACTA BIOCHIMICA POLONICA, vol. 69, 1 March 2021 (2021-03-01), PL, pages 101 - 111, XP093002499, ISSN: 0001-527X, DOI: 10.18388/abp.2020_5746 * |
ZAMORE ET AL., CELL, vol. 101, no. 1, 2000, pages 25 - 33 |
ZAMORE ET AL., CELL., vol. 101, no. 1, 2000, pages 25 - 33 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Parrotta et al. | A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair | |
US20230090446A1 (en) | Antisense oligonucleotide targeting linc00518 for treating melanoma | |
EP3020828A1 (fr) | Procédé de prédiction de réponse d'un cancer à un traitement | |
Liang et al. | MicroRNA-873 acts as a tumor suppressor in esophageal cancer by inhibiting differentiated embryonic chondrocyte expressed gene 2 | |
Chuang et al. | Functional role of the long noncoding RNA X-inactive specific transcript in leiomyoma pathogenesis | |
JP2020534354A (ja) | トリプルネガティブ乳癌の治療方法 | |
Wang et al. | RETRACTED ARTICLE: miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1 | |
WO2018112342A1 (fr) | Inhibiteurs chimiques contre les kinases pour bloquer l'élongation des télomères dans le cancer | |
WO2017005773A1 (fr) | Utilisation de micro-arn ciblant la bêta-caténine pour le traitement du cancer du foie | |
EP2658972A2 (fr) | Traitements de mélanomes | |
US9187787B2 (en) | Method of diagnosing and treating cancer | |
Zhang et al. | Hsa_circular RNA_0045474 Facilitates Osteoarthritis Via Modulating microRNA-485-3p and Augmenting Transcription Factor 4 | |
WO2024003350A1 (fr) | Polythérapie pour mélanome | |
EP4299742A1 (fr) | Thérapie combinée pour mélanome | |
EP3121274A1 (fr) | MÉTHODE PERMETTANT DE PRÉVOIR LA SENSIBILITÉ À UN TRAITEMENT ANTICANCÉREUX AU MOYEN D'UN COMPOSÉ INHIBITEUR DE p300 | |
KR20190005727A (ko) | 난소과립막세포암 또는 자궁내막암의 진단 및 치료를 위한 마이크로rna-1236의 용도 | |
US9139829B2 (en) | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment | |
Liu et al. | FOSL1 transcriptionally regulates PHLDA2 to promote 5-FU resistance in colon cancer cells | |
KR102293777B1 (ko) | 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법 | |
KR20230045386A (ko) | miR-4487를 유효성분으로 함유하는 항암제 민감성 증진용 조성물 | |
JP2010529852A (ja) | 癌治療のためのNuMAのRNAi媒介ノックダウン | |
US20230340607A1 (en) | Compositions and methods for detecting gene fusions of rad51ap1 and dyrk4 and for diagnosing and treating cancer | |
JP7097606B2 (ja) | 二本鎖核酸分子、dna、ベクター、がん細胞増殖抑制剤、医薬、及びspon1-trim29融合遺伝子の利用 | |
AU2022384267A1 (en) | Lncrna transcripts in melanomagenesis | |
JP2009501024A (ja) | 癌の診断及び治療における遺伝的及びエピジェネティックな変化 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23736701 Country of ref document: EP Kind code of ref document: A1 |